Cancer treatment using PRMT5 inhibitors
JNJ-64619178, a selective PRMT5 inhibitor, addresses the need for effective cancer treatment by using a dosing schedule with on/off cycles to suppress tumors effectively and minimize toxicity.
Patent Information
- Application Number
- JP2021571834
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-08-27
- Filing Date
- 2020-06-05
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-06-05
AI Technical Summary
There is a lack of selective PRMT5 inhibitors for the treatment or prevention of cancer, as PRMT5 is considered a clinically relevant target but few effective inhibitors have been developed.
The use of JNJ-64619178, a potent and selective small molecule inhibitor of PRMT5, which binds to the substrate pocket of the PRMT5-MEP50 complex, is administered in a specific dosing schedule that includes on/off cycles to maintain tumor suppression and reduce toxicity.
JNJ-64619178 demonstrates regression and cure in human xenograft models with tolerated doses, maintaining plasma drug concentrations during washout periods and reducing toxicity, while providing long-term pharmacodynamic control over tumor growth.
Smart Images

Figure 0007590351000010 
Figure 0007590351000011 
Figure 0007590351000012
Abstract
Description
[Technical field]
[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of U.S. Provisional Patent Application No. 62 / 858,076, filed June 6, 2019, and European Patent Application Publication No. 19193850.5, filed August 27, 2019, the disclosures of which are incorporated herein by reference in their entireties.
[0002] FIELD OF THEINVENTION The present invention relates to methods of treating cancer using PRMT5 inhibitors. [Background technology]
[0003] Protein arginine methyltransferase 5 (PRMT5), also described as Hsl7, Jbp1, Skb1, Capsuleen, or Dart5, is one of the major methyltransferases involved in mono- and symmetric dimethylation of arginine. Post-translational arginine methylation on histone and non-histone proteins appears to be important for various biological processes such as genome organization, transcription, differentiation, splicosome function, cell cycle signaling and control, stem cells, and T cell fate. Metazoan PRMT5 forms a functional complex with Wdr77, androgen receptor coactivator p44, and methylosome protein 50 (MEP50), also called Valois. Both elevated protein concentrations and cytoplasmic accumulation of PRMT5-MEP50 are involved in cancer tumorigenesis and correlate with poor clinical outcomes. Cell rescue experiments addressing both the catalytic and scaffolding functions of the PRMT5-MEP50 complex, as well as comprehensive enzymological studies, have demonstrated an oncogenic link between protein concentration, localization, and enzymatic function, making PRMT5 an important small molecule drug target for cancer and other diseases. Summary of the Invention [Problem to be solved by the invention]
[0004] Although PRMT5 is considered a clinically relevant target, few selective PRMT5 inhibitors have been developed.Therefore, there is a strong need for new therapeutic regimens that include PRMT5 inhibitors for the treatment or prevention of cancer.Therefore, it is an object of the present invention to provide such a method. [Means for solving the problem]
[0005] JNJ-64619178 is a potent and selective small molecule inhibitor across a range of heme and solid tumor cell lines, with potential distinguishing properties in that it simultaneously binds to the SAM cofactor and the substrate pocket of the (PRMT5)4 / (MEP50)4 complex (methylosome) with a long residence time, especially compared to other PRMT5 inhibitors. In vivo data has demonstrated regression / cure in all human xenograft models tested at tolerated doses, with no ADME or expressivity issues, and with a PK and toxicity profile suitable for oral dosing in humans no more than once daily.
[0006] In certain embodiments, the disclosure provides a method for treating a human patient diagnosed with cancer comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, the method comprising: (i) administering to the patient an initial dose of at least about 0.1 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 5 to about 20 days; and (ii) administering to the patient subsequent doses of the PRMT5 inhibitor of at least about 0.1 mg per day for one or more subsequent dosing periods of about 5 to about 20 days each. In these methods, the first subsequent administration period is spaced in time by at least about 5 days from the first administration period, and / or the subsequent administration periods are spaced in time by at least about 5 days from each other.
[0007] In a further embodiment, the disclosure provides a method for treating a human patient diagnosed with cancer comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, the method comprising: (i) administering to the patient an initial dose of at least about 0.1 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 5 to about 21 days; and (ii) administering to the patient subsequent doses of the PRMT5 inhibitor of at least about 0.1 mg per day for one or more subsequent dosing periods of about 5 to about 21 days each. In these methods, the first subsequent administration period is spaced in time by at least about 5 days from the first administration period, and / or the subsequent administration periods are spaced in time by at least about 5 days from each other.
[0008] In other embodiments, the disclosure provides a method for treating a human patient diagnosed with cancer comprising administering a therapeutically effective amount of a PRMT5 inhibitor, the method comprising: (i) administering to the patient an initial dose of at least about 0.1 mg per day of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 14 days; and (ii) administering to the patient a subsequent dose of at least about 0.1 mg per day of the PRMT5 inhibitor for one or more subsequent dosing periods. In these methods, the first subsequent administration period is spaced in time by at least about 7 days from the first administration period, and / or the subsequent administration periods are spaced in time by at least about 7 days from each other.
[0009] In a further embodiment, the disclosure provides a method for treating a human patient diagnosed with cancer comprising administering a therapeutically effective amount of a PRMT5 inhibitor, the method comprising: (i) administering an initial dose of at least about 0.1 mg per day of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days; (iii) after the off period, administering a subsequent dose of at least about 0.1 mg of the PRMT5 inhibitor per day to the patient for a subsequent dosing period of about 14 days; (iv) after the subsequent dosing period, not administering the compound to the patient for an off period of about 7 days; and (v) optionally, continuously repeating steps (iii) and (iv).
[0010] In other embodiments, the disclosure provides a method for treating a human patient diagnosed with cancer, comprising administering a therapeutically effective amount of a PRMT5 inhibitor, the method comprising: (i) administering an initial dose of at least about 0.1 mg per day of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutical acceptable addition salt or solvate thereof, for about 1 hour; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 14 days; (iii) after the off period, administering a subsequent dose of at least about 0.1 mg of the PRMT5 inhibitor per day to the patient for a subsequent dosing period of about 14 days; (iv) after the subsequent dosing period, not administering the compound to the patient for an off period of about 14 days; and (v) optionally, continuously repeating steps (iii) and (iv).
[0011] In yet another embodiment, the disclosure provides a method for treating a human patient diagnosed with cancer comprising administering a therapeutically effective amount of a PRMT5 inhibitor, the method comprising: (i) administering an initial dose of at least about 0.1 mg per day of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days; (iii) after the off period, administering a subsequent dose of at least about 0.1 mg of the PRMT5 inhibitor per day to the patient for a subsequent dosing period of about 7 days; (iv) after the subsequent dosing period, not administering the compound to the patient for an off period of about 7 days; and (v) optionally, continuously repeating steps (iii) and (iv).
[0012] In yet a further embodiment, the disclosure provides a protein arginine methyltransferase 5 (PRMT5) inhibitor for use in treating a human patient diagnosed with cancer by administration of a therapeutically effective amount of a PRMT5 inhibitor to the human patient, the administration comprising: (i) at least about 0.1 mg / day of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol; and (ii) administering to the patient an initial dose of a PRMT5 inhibitor, the PRMT5 inhibitor being at least about 0.1 mg per day, over an initial administration period of about 5 to about 20 days, and (iii) administering to the patient subsequent doses of the PRMT5 inhibitor of at least about 0.1 mg per day over one or more subsequent administration periods of about 5 to about 20 days each, wherein the first subsequent administration period is separated in time by at least about 5 days from the initial administration period and the subsequent administration periods are separated in time by at least about 5 days from each other.
[0013] In a further embodiment, the disclosure provides a protein arginine methyltransferase 5 (PRMT5) inhibitor for use in treating a human patient diagnosed with cancer by administration to the human patient of a therapeutically effective amount of a PRMT5 inhibitor, the administration comprising: (i) at least about 0.1 mg per day of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol; or a pharmaceutically acceptable addition salt or solvate thereof, over an initial administration period of about 5 to about 21 days; and (ii) administering to the patient subsequent doses of at least about 0.1 mg of the PRMT5 inhibitor per day over one or more subsequent administration periods of about 5 to about 21 days each, wherein the first subsequent administration period is separated in time by at least about 5 days from the initial administration period, and the subsequent administration periods are separated in time by at least about 5 days from each other.
[0014] In another embodiment, the disclosure provides a PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer, the method comprising administering to the human patient a therapeutically effective amount of a PRMT5 inhibitor, the method comprising: (i) administering to the patient an initial dose of at least about 0.1 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 5 to about 20 days; and (ii) administering to the patient subsequent doses of the PRMT5 inhibitor of at least about 0.1 mg per day for one or more subsequent dosing periods of about 5 to about 20 days each. The first subsequent dosing period is spaced in time from the first dosing period by at least about 5 days, and the subsequent dosing periods are spaced in time from each other by at least about 5 days.
[0015] In still further embodiments, the disclosure provides a PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer, the method comprising administering to the human patient a therapeutically effective amount of a PRMT5 inhibitor, the method comprising: (i) administering at least about 0.1 mg per day of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2- (ii) administering to the patient an initial dose of a PRMT5 inhibitor, which is a diol or a pharma- ceutically acceptable addition salt or solvate thereof, over an initial administration period of about 5 to about 21 days; and (ii) administering to the patient subsequent doses of at least about 0.1 mg of the PRMT5 inhibitor per day over one or more subsequent administration periods, each of about 5 to about 21 days, wherein a first subsequent administration period is separated in time by at least about 5 days from the initial administration period, and the subsequent administration periods are separated in time by at least about 5 days from each other.
[0016] In other embodiments, the disclosure provides a method for treating a human patient diagnosed with cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, the method comprising administering to the patient a sustained dose of up to about 2 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an administration period of at least about 21 days. In some aspects, the sustained dose is about 1 mg to about 2 mg of the PRMT5 inhibitor per day. In other aspects, the sustained dose is about 1 mg of the PRMT5 inhibitor per day. In further aspects, the sustained dose is about 2 mg of the PRMT5 inhibitor per day.
[0017] In further embodiments, the disclosure provides a PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer, the method comprising administering a therapeutically effective amount of a PRMT5 inhibitor to the human patient, the method comprising administering to the patient a sustained dose of up to about 2 mg per day of the PRMT5 inhibitor, the PRMT5 inhibitor being (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an administration period of at least about 21 days. In some aspects, the sustained dose is about 1 mg to about 2 mg of the PRMT5 inhibitor per day. In other aspects, the sustained dose is about 1 mg of the PRMT5 inhibitor per day. In a further embodiment, the sustained dose is about 2 mg of the PRMT5 inhibitor per day.
[0018] In yet a further embodiment, the present disclosure provides a PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer by administration to the human patient of a therapeutically effective amount of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof. The administration comprises: (i) administering to the patient an initial dose of at least about 0.1 mg of the PRMT5 inhibitor per day for an initial administration period of about 5 to about 20 days; and (ii) administering to the patient subsequent doses of at least about 0.1 mg of the PRMT5 inhibitor per day for one or more subsequent administration periods of about 5 to about 20 days each, wherein a first subsequent administration period is separated in time by at least about 5 days from the initial administration period, and the subsequent administration periods are separated in time by at least about 5 days from each other.
[0019] In a further embodiment, the disclosure provides a PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer by administration to the human patient of a therapeutically effective amount of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof. The administering comprises: (i) administering to the patient an initial dose of at least about 0.1 mg of the PRMT5 inhibitor per day for an initial administration period of about 5 to about 21 days; and (ii) administering to the patient subsequent doses of at least about 0.1 mg of the PRMT5 inhibitor per day for one or more subsequent administration periods, each of about 5 to about 21 days, wherein the first subsequent administration period is separated in time by at least about 5 days from the initial administration period, and the subsequent administration periods are separated in time by at least about 5 days from each other.
[0020] In another embodiment, the disclosure provides a PRMT5 (protein arginine methyltransferase 5) inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for use in treating a human patient diagnosed with cancer, the method comprising administering a therapeutically effective amount of the PRMT5 inhibitor to the human patient. the method comprising: (i) administering to the patient an initial dose of at least about 0.1 mg of a PRMT5 inhibitor per day for an initial administration period of about 5 to about 20 days; and (ii) administering to the patient a subsequent dose of at least about 0.1 mg of a PRMT5 inhibitor per day for one or more subsequent administration periods of about 5 to about 20 days each, wherein a first subsequent administration period is separated in time by at least about 5 days from the initial administration period, and the subsequent administration periods are separated in time by at least about 5 days from each other.
[0021] In still a further embodiment, the disclosure provides a PRMT5 (protein arginine methyltransferase 5) inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for use in treating a human patient diagnosed with cancer, the method comprising administering a therapeutically effective amount of the PRMT5 inhibitor to the human patient. The method comprises: (i) administering to the patient an initial dose of at least about 0.1 mg of a PRMT5 inhibitor per day for an initial administration period of about 5 to about 21 days; and (ii) administering to the patient a subsequent dose of at least about 0.1 mg of a PRMT5 inhibitor per day for one or more subsequent administration periods of about 5 to about 21 days each, wherein a first subsequent administration period is separated in time by at least about 5 days from the initial administration period, and the subsequent administration periods are separated in time by at least about 5 days from each other.
[0022] In further embodiments, the disclosure provides a PRMT5 (protein arginine methyltransferase 5) inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for use in treating a human patient diagnosed with cancer, the method comprising administering a therapeutically effective amount of a PRMT5 inhibitor to the human patient, the method comprising administering to the patient a sustained dose of up to about 2 mg of the PRMT5 inhibitor per day for an administration period of at least about 21 days. In some aspects, the sustained dose is about 1 mg to about 2 mg of the PRMT5 inhibitor per day. In other aspects, the sustained dose is about 1 mg of the PRMT5 inhibitor per day. In a further aspect, the sustained dose is about 2 mg of PRMT5 inhibitor per day. In the following sections, the various aspects and embodiments of the present disclosure are defined in more detail. Each aspect or embodiment so defined may be combined with any other embodiment or aspect, unless otherwise clearly indicated by the context. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.
[0023] In embodiments of the invention relating to the use of a PRMT5 inhibitor (e.g., (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof) in the manufacture of a medicament for the treatment of a patient (e.g., a human patient) diagnosed with cancer, references to "administering" and "administration" of a PRMT5 inhibitor include the medicament prepared for such administration. For example, as well as embodiments relating to "administering a therapeutically effective amount of a PRMT5 inhibitor," the invention also relates to embodiments where "PRMT5 is prepared for administration in a therapeutically effective amount." [Brief description of the drawings]
[0024] [Figure 1] FIG. 1 is a line graph showing inhibition of growth of expanded tumors using cessation of dosing of a compound of the present disclosure in a NCI-H1048 tumor model (monitoring tumor regrowth after cessation of dosing of JNJ-64619178 in human SCLC mouse xenografts). [Diagram 2] FIG. 1 is a line graph showing long-term pharmacodynamic modulation following treatment of NCI-H1048 cells with compounds of the present disclosure (mean tumor volume of human SCLC mouse xenografts with compounds once daily for 28 days). [Diagram 3] Box plot showing SmD1 / 3-Me2 concentrations after oral administration of JNJ64619178 (10 mg / kg) to NCI-H1048 lung cancer xenograft mice for 9 consecutive days (gray area) followed by cessation of treatment for 11 days. The percentage (%) of SmD1 / 3-Me2 concentrations compared to the vehicle-treated group (defined as 100%) is visualized as a box plot with whiskers from minimum to maximum values and median values connected by a line. The dotted bars represent the concentration of SmD1 / 3-Me2 in untreated samples. [Figure 4] 1 is a line graph showing the inhibition of the growth of expanded tumors using the administration of JNJ64619178 (10mg / kg) for 28 consecutive days, or the administration of 7 days of daily drug treatment followed by 7 days of rest period for two cycles (7+ / 7-, 2 cycles) of the compound of the present disclosure in NCI-H1048 tumor model.Tumor growth inhibition (TGI,%) is calculated on the 28th day compared to vehicle treatment, which is 62% and 63%, respectively. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0025] JNJ-64619178 is an S-adenosylmethionine (SAM) competitive small molecule inhibitor of PRMT5 / MEP50 that exhibits slow off-rate binding kinetics as demonstrated by surface plasmon resonance binding studies. Additional in vitro thermal shift experiments show that JNJ-64619178 binding further stabilizes the PRMT5 / MEP50 complex by 12°C compared to SAM binding. Co-crystallization of JNJ-64619178 with PRMT5 / MEP50 shows that binding is within the SAM binding pocket. The additional binding of JNJ-64619178 to the protein substrate binding pocket appears to trap the entire PRMT5 / MEP50 protein complex in an inactive state, explaining the molecular mechanism of the slow off-rate binding kinetics. This unique binding mode produces highly potent and time-dependent PRMT5 enzyme inhibition.
[0026] As described herein, the methods are directed to treating human patients diagnosed with cancer by using (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol (a PRMT5 inhibitor also referred to as JNJ-64619178) and a new dosing schedule. According to certain embodiments, dosing schedules that include "on / off dosing cycles" not only result in comparable or better efficacy of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol (e.g., compared to a continuous dosing cycle, in which there is no "off period"), but may also provide long-term pharmacodynamic control during periods when (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol is not administered to the patient. Thus, according to certain embodiments, tumor growth continues to be suppressed and plasma drug concentrations are maintained during washout periods, i.e., "off periods" ("off periods"). Preferably, a dosing schedule with "off periods" may have a lower toxicity risk compared to a continuous dosing schedule without an "off period". A dosing schedule with "off periods" may also, or alternatively, result in earlier recovery from toxicity compared to that seen when using a continuous dosing schedule without an "off period". According to certain embodiments, a patient administered a JNJ-64619178 PRMT5 inhibitor according to a dosing schedule that includes "on / off dosing cycles" over a period of time (e.g., 3 months, 6 months, 9 months, 12 months, 18 months, or 24 months) may experience less toxicity compared to a patient administered the same dose of a JNJ-64619178 PRMT5 inhibitor over the same period of time, but according to a "continuous" dosing schedule without an "off period".According to other embodiments, a patient administered a JNJ-64619178 PRMT5 inhibitor according to a dosing schedule that includes "on / off dosing cycles" over a period of time (e.g., 3 months, 6 months, 9 months, 12 months, 18 months, or 24 months) may experience fewer dosing interruptions compared to a patient administered the same dose of a JNJ-64619178 PRMT5 inhibitor over the same period of time but according to a "continuous" dosing schedule without the "off periods."
[0027] As described herein, the disclosure provides a method for treating a human patient diagnosed with cancer by a continuous dosing regimen. Such methods lack "off periods" and therefore provide a consistent daily pharmacokinetic profile. Such methods include administering a sustained dose of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable addition salt or solvate thereof. In some embodiments, the administration period is at least about 21 days. In some aspects, the sustained dose is about 1 mg to about 2 mg of the PRMT5 inhibitor per day. In other aspects, the sustained dose is about 1 mg of the PRMT5 inhibitor per day. In further aspects, the sustained dose is about 2 mg of the PRMT5 inhibitor per day.
[0028] The method of the present disclosure includes administering a therapeutically effective amount of a PRMT5 inhibitor. The term "therapeutically effective amount" refers to an amount (e.g., of an active compound, such as a compound of the present disclosure, or a pharmaceutical agent) that induces a biological or medicinal response in a tissue system, animal, or human that a researcher, veterinarian, physician, or other clinical professional seeks to obtain, such as reducing or inhibiting an enzyme or protein activity, or improving symptoms, alleviating a pathology, slowing or delaying disease progression, or preventing a disease. In other words, the term therapeutically effective amount can refer to an amount that, when administered to a particular subject, achieves a therapeutic effect by inhibiting, alleviating, or curing a disease, condition, syndrome, or disorder in the subject, or by prophylactically inhibiting, preventing, or delaying the onset of a disease, condition, syndrome, or disorder, or symptoms thereof. A therapeutically effective amount can be an amount that relieves to some extent one or more symptoms of a disease, condition, syndrome, or disorder in a subject; and / or partially or completely restores to normal one or more physiological or biochemical parameters associated with or causing the disease, condition, syndrome, or disorder; and / or reduces the likelihood of development of the disease, condition, syndrome, or disorder, or symptoms thereof.
[0029] As used herein, the term "PRMT5 inhibitor" or "protein arginine methyltransferase 5 inhibitor" refers to a chemical compound that inhibits the enzymatic activity of protein arginine methyltransferase 5. In some embodiments, the PRMT5 inhibitor is a compound described herein. In other embodiments, the PRMT5 inhibitor is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof. In a further embodiment, the PRMT5 inhibitor is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol. In yet another embodiment, the PRMT5 inhibitor is a salt of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol. In yet a further embodiment, the PRMT5 inhibitor is a solvate of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol. Unless otherwise stated herein, one skilled in the art will understand that the PRMT5 inhibitor used in the subsequent administration is the same as the PRMT5 inhibitor used in the initial administration.
[0030] According to certain embodiments, the efficacy of the methods described herein is measured by techniques such as determining the patient's time to disease progression or patient response rate. Thus, efficacy can be useful in determining whether treatment can be continued or discontinued. In some embodiments, efficacy is measured by the patient's time to disease progression, e.g., a decrease in disease progression over time in response to treatment with the disclosed methods. Disease progression can be measured by cancer cell proliferation (local or systemic) and / or recurrence of disease side effects and / or occurrence of new disease side effects. Thus, in some embodiments, the methods described herein desirably increase the patient's time to disease progression relative to the patient's disease progression before the method was started.
[0031] In other embodiments, efficacy is measured by determining patient response rate. As used herein, "response rate" is the ratio of the number of patients who respond to treatment (due to the demonstration of efficacy) to the number of patients who are receiving treatment. Those skilled in the art will be able to easily evaluate the patient response rate using standard classifications and criteria, including but not limited to the Lugano staging (see Table 1) and Response Evaluation Criteria in Solid Tumors (RECIST). See, for example, Eisenhauer et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, 45: 228-247 (2009), which is incorporated herein by reference. As described herein, a complete response (CR) includes disappearance of all target lesions, a partial response (PR) includes at least a 30% decrease in the sum of diameters of target lesions based on the baseline sum of diameters, a progressive disease (PD) includes at least a 20% increase in the sum of diameters of target lesions based on the smallest sum of diameters on trial (including the baseline sum if smallest on trial), and a stable disease (SD) includes neither sufficient shrinkage for PR nor sufficient increase for PD based on the smallest sum of diameters on trial.
[0032] [Table 1]
[0033] According to certain embodiments, the method of the present invention is effective in causing a complete response (CR), or a partial response (PR), or a stable disease (SD) in a patient according to RECIST criteria. In one embodiment, the method of the present invention is effective in causing a complete response (CR) in a patient according to RECIST criteria. In one embodiment, the method of the present invention is effective in causing a partial response (PR) in a patient according to RECIST criteria. In one embodiment, the method of the present invention is effective in causing a stable disease (SD) in a patient according to RECIST criteria, optionally with the disease being stable for more than 6 months.
[0034] According to certain embodiments, the efficacy of the disclosed therapeutic methods may be measured by one or more of the following: reduced proliferation of cancer cells (local or systemic), absence of cancer cells (local or systemic), reduced side effects of the disease, or absence of side effects of the disease. In some embodiments, the methods of the present invention are effective in treating solid cancers or hematological cancers.
[0035] In some aspects, the methods are effective in treating solid tumors, such as by reducing tumor volume in a patient. In some embodiments, the patient's tumor volume is reduced by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% after treatment. In other embodiments, the methods are effective in reducing tumor volume by at least about 30% or about 35%.
[0036] In other aspects, the method is effective in treating hematological cancers, for example, by stabilizing one or more hematological parameters. Examples of hematological parameters that can be measured to assess efficacy include, but are not limited to, complete blood counts, e.g., red blood cells (RBCs), white blood cells (neutrophils, eosinophils, basophils, monocytes and lymphocytes), platelets, hemoglobin, hematocrit, or combinations thereof. The efficacy of the claimed method in treating hematological cancers can be measured by RBC transfusion independence (TI) rate, overall improvement rate (complete response, partial response, and hematological improvement), or combinations thereof. In some embodiments, the response criteria for MDS patients are determined using the International Working Group response criteria (modified). See, e.g., Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia, Blood, 108:419-425, 2006, incorporated herein by reference.
[0037] In other embodiments, the methods allow the patient to maintain a stable disease state or condition, ie, the cancer does not progress or otherwise adversely affect the patient.
[0038] According to further embodiments, the treatment is effective to put the patient into remission from cancer.
[0039] As detailed herein, the method includes administering an initial dose of a PRMT5 inhibitor to the patient, e.g., daily, for an initial administration period. In some embodiments, the patient is already taking a PRMT5 inhibitor daily. In other embodiments, the patient has not yet been administered a PRMT5 inhibitor. As used herein, the term "initial administration period" refers to a period during which administration of a PRMT5 inhibitor or the implementation of the method described herein begins.
[0040] According to certain embodiments, the initial administration period is about 5 to about 20 days or about 5 to about 21 days. In some embodiments, the initial administration period is about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, or about 21 days. In some embodiments, the initial administration period is about 7 days to about 14 days. In further embodiments, the initial administration period is about 7 days. In yet other embodiments, the initial administration period is about 14 days.
[0041] The method also includes administering to the patient, for example, daily, the PRMT5 inhibitor for one or more subsequent administration periods. In some embodiments, the PRMT5 inhibitor used in the subsequent administration is the same as the PRMT5 inhibitor used in the initial administration. As used herein, the term "subsequent administration period" refers to a period following the initial administration period. The attending physician or another clinician may be able to determine the number of subsequent administration periods that will provide a therapeutic effect or clinical benefit. The attending physician or another clinician may also be able to determine when treatment may be discontinued. Desirably, the subsequent administration period continues, provided that the patient experiences one or more clinical benefits from the treatment. In some embodiments, the subsequent administration period continues until the patient goes into remission from the disease or condition, e.g., cancer, that prompted the administration of the PRMT5 inhibitor, in which case administration of the PRMT5 inhibitor may be discontinued. In other embodiments, the subsequent administration period continues until the patient exhibits an increase in cancer cells and / or tumor volume. In further embodiments, the subsequent administration period continues, provided that the treatment is tolerable to the patient. For example, the follow-on dosing period may continue until the patient experiences an adverse event such that discontinuation of the PRMT5 inhibitor outweighs the severity of the adverse event.
[0042] According to certain embodiments, the one or more subsequent administration periods are each about 5 to about 20 days or about 5 to about 21 days. In some embodiments, the one or more subsequent administration periods are about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, or about 21 days. In some embodiments, the one or more subsequent administration periods are about 7 days to about 14 days. In further embodiments, the one or more subsequent administration periods are about 7 days. In yet other embodiments, the one or more subsequent administration periods are about 14 days.
[0043] The first subsequent administration period is spaced apart from the initial administration period by a period of time. This period is also referred to as the "first drug holiday" or "off period." During this first drug holiday, the PRMT5 inhibitor is not administered to the patient. In some embodiments, the first subsequent administration period is spaced apart from the initial administration period by at least about 5 days. That is, the first drug holiday is at least about 5 days. In some embodiments, the first subsequent administration period is about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days. In further embodiments, the first drug holiday is about 7 days to about 14 days. In other embodiments, the first drug holiday is about 7 days. In still further embodiments, the first drug holiday is about 14 days. In still other embodiments, the initial administration period is about 14 days and the first drug holiday is about 7 days. In yet another embodiment, the initial administration period is about 7 days and the first rest period is about 7 days. In yet another embodiment, the initial administration period is about 7 days and the first rest period is about 14 days. In yet another embodiment, the initial administration period is about 14 days, the first rest period is about 7 days, and one or more subsequent administration periods are about 14 days. In yet another embodiment, the initial administration period is about 7 days, the first rest period is about 7 days, and one or more subsequent administration periods are about 7 days. In yet another embodiment, the initial administration period is about 7 days, the first rest period is about 14 days, and one or more subsequent administration periods are about 7 days.
[0044] Each of the subsequent administration periods is spaced apart from the other by a period of time, i.e., a "drug holiday" or "off period." During these subsequent drug holidays, the PRMT5 inhibitor is not administered to the patient. In some embodiments, the subsequent administration periods are spaced apart in time from each other by at least about 5 days. In further embodiments, the subsequent administration periods are spaced apart in time from each other by at least about 7 days. In some embodiments, the subsequent administration periods are spaced apart in time from each other by about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days. In other embodiments, the subsequent administration periods are spaced apart in time from each other by at least about 14 days. In yet further embodiments, the subsequent administration periods are spaced apart in time from each other by at least about 7 days.
[0045] In certain methods, the first subsequent administration period is spaced in time from the first administration period by at least about 7 days, and the subsequent administration periods are spaced in time from each other by at least about 7 days. In further embodiments, the first subsequent administration period is spaced in time from the first administration period by about 7 days, and the subsequent administration periods are spaced in time from each other by about 7 days. The subsequent administration periods, subsequent off periods, or combinations thereof may be repeated continuously.
[0046] Each dose, i.e., the first dose or the subsequent dose, may be determined depending on factors such as the route of administration, the age and condition of the patient, and the specific disorder or disease being treated. The first dose and at least one subsequent dose may be the same or different. In certain embodiments, the first dose and at least one subsequent dose are the same. In other embodiments, the first dose and at least one subsequent dose are different. In certain embodiments, the first dose and the subsequent dose are the same.
[0047] The first dose and each of the subsequent doses may be administered daily. The doses (both the first dose and each subsequent dose) may be administered as a single dose, i.e., once a day, or as split doses. In some embodiments, the first dose is administered once a day. In other embodiments, each subsequent dose is administered once a day. In further embodiments, both the first dose and at least one subsequent dose are administered once a day. The doses may also be split doses. As used herein, the term "split dose" refers to the administration of at least two doses per day. Thus, for example, "split dose" refers to twice per day (BID), three times per day (TID), or four times per day (QID). In certain embodiments, the first dose is a split dose. In other embodiments, each of the subsequent doses is a split dose. In further embodiments, the first dose and at least one subsequent dose are administered in split doses. Each dose of the split dose may be the same or different. In some embodiments, the fractional doses of the first dose are the same or equal. In other embodiments, the fractional doses of the first dose are different. In further embodiments, the fractional doses of each subsequent dose are the same or equal. In yet other embodiments, the fractional doses of each subsequent dose are different. In further embodiments, the fractional doses of the first dose and each subsequent dose are equal. In still other embodiments, the first dose is administered twice daily. In still further embodiments, the first dose is administered three times daily. In other embodiments, the first dose is administered four times per day. In further embodiments, each subsequent dose is administered twice daily. In still other embodiments, each subsequent dose is administered three times per day. In still further embodiments, each subsequent dose is administered four times per day. In other embodiments, the first dose or each of the at least one subsequent dose is administered twice daily in a divided dose. In further embodiments, both the first dose and the at least one subsequent dose are administered twice daily in a divided dose.
[0048] The initial dose per day, i.e., the daily dose, is independently at least about 0.1 mg. In some embodiments, the initial dose per day is at least about 0.1 mg. In further embodiments, the initial dose per day is at least about 0.5 mg, at least about 1 mg, at least about 1.5 mg, at least about 2 mg, at least about 3 mg, at least about 4 mg, at least about 5 mg, at least about 5.5 mg, at least about 6 mg, at least about 8 mg, at least about 16 mg, at least about 30 mg, or at least about 60 mg. In still further embodiments, the initial dose per day is about 0.5 mg. In other embodiments, the initial dose per day is about 1 mg. In other embodiments, the initial dose per day is about 1.5 mg. In further embodiments, the initial dose per day is about 2 mg. In other embodiments, the initial dose per day is about 2.5 mg. In yet other embodiments, the initial dose per day is about 3 mg. In other embodiments, the initial dose per day is about 3.5 mg. In yet further embodiments, the initial dose per day is about 4 mg. In other embodiments, the initial dose per day is about 4.5 mg. In other embodiments, the initial dose per day is about 5 mg. In further embodiments, the initial dose per day is about 5.5 mg. In yet other embodiments, the initial dose per day is about 6 mg. In still further embodiments, the initial dose per day is about 8 mg. In other embodiments, the initial dose per day is about 12.5 mg. In further embodiments, the initial dose per day is about 16 mg. In yet other embodiments, the initial dose per day is about 25 mg.
[0049] In another embodiment, each of the initial doses per day is about 0.1 to about 100 mg. In a further embodiment, each of the initial doses per day is about 0.5 to about 80 mg. In yet another embodiment, each of the initial doses per day is about 0.5 to about 60 mg. In yet a further embodiment, each of the initial doses per day is about 0.5 to about 30 mg. In another embodiment, each of the initial doses per day is about 0.5 to about 16 mg. In yet another embodiment, each of the initial doses per day is about 0.5 to about 8 mg. In yet another embodiment, each of the initial doses per day is about 0.5 to about 5 mg. In yet another embodiment, each of the initial doses per day is about 0.5 to about 4 mg. In yet a further embodiment, each of the initial doses per day is about 0.5 to about 2 mg. In another embodiment, each of the initial doses per day is about 0.5 to about 1 mg. In further embodiments, each initial dose per day is about 1 to about 8 mg. In yet other embodiments, each initial dose per day is about 1 to about 5 mg. In yet other embodiments, each initial dose per day is about 1 to about 4 mg. In yet further embodiments, each initial dose per day is about 1 to about 2 mg.
[0050] Each of the subsequent doses may be the same or different. In some embodiments, the subsequent doses may be the same for a period of time during the method and then vary for another period of time during the method. In other embodiments, the subsequent doses may be the same throughout the method. Thus, each of the subsequent doses per day, i.e., the subsequent daily doses, is independently at least about 0.1 mg. In some further embodiments, the subsequent doses per day are at least about 0.1 mg. In further embodiments, the subsequent doses are at least about 0.5 mg, at least about 1 mg, at least about 1.5 mg, at least about 2 mg, at least about 3 mg, at least about 4 mg, at least about 5 mg, at least about 5.5 mg, at least about 6 mg, at least about 8 mg, at least about 16 mg, at least about 30 mg, or at least about 60 mg. In still further embodiments, each subsequent dose per day is about 0.5 mg. In other embodiments, each subsequent dose per day is about 1 mg. In other embodiments, each subsequent dose per day is about 1.5 mg. In further embodiments, each subsequent dose per day is about 2 mg. In other embodiments, each subsequent dose per day is about 2.5 mg. In yet other embodiments, each subsequent dose per day is about 3 mg. In other embodiments, each subsequent dose per day is about 3.5 mg. In still further embodiments, each subsequent dose per day is about 4 mg. In other embodiments, each subsequent dose per day is about 4.5 mg. In other embodiments, each subsequent dose per day is about 5 mg. In further embodiments, each subsequent dose per day is about 5.5 mg. In still other embodiments, each subsequent dose per day is about 6 mg. In still further embodiments, each subsequent dose per day is about 8 mg. In other embodiments, each subsequent dose per day is about 12.5 mg. In further embodiments, each subsequent dose per day is about 16 mg. In yet other embodiments, each subsequent dose per day is about 25 mg.
[0051] In some cases, the initial dose and the subsequent dose are the same. In some embodiments, the initial dose per day is about 1.5 mg, and the subsequent dose per day is about 1.5 mg. In other embodiments, the initial dose per day is about 1 mg, and the subsequent dose per day is about 1 mg. In further embodiments, the initial dose per day is about 2 mg, and the subsequent dose per day is about 2 mg.
[0052] In other embodiments, each of the subsequent doses per day is about 0.1 to about 100 mg. In further embodiments, each of the subsequent doses per day is about 0.5 to about 80 mg. In yet other embodiments, each of the subsequent doses per day is about 0.5 to about 60 mg. In still further embodiments, each of the subsequent doses per day is about 0.5 to about 30 mg. In other embodiments, each of the subsequent doses per day is about 0.5 to about 16 mg. In still other embodiments, each of the subsequent doses per day is about 0.5 to about 8 mg. In still other embodiments, each of the subsequent doses per day is about 0.5 to about 5 mg. In still other embodiments, each of the subsequent doses per day is about 0.5 to about 4 mg. In still further embodiments, each of the subsequent doses per day is about 0.5 to about 2 mg. In other embodiments, each of the subsequent doses per day is about 0.5 to about 1 mg. In further embodiments, each of the subsequent daily doses is from about 1 to about 8 mg. In yet other embodiments, each of the subsequent daily doses is from about 1 to about 5 mg. In yet other embodiments, each of the subsequent daily doses is from about 1 to about 4 mg. In yet further embodiments, each of the subsequent daily doses is from about 1 to about 2 mg.
[0053] In certain aspects, the disclosure provides a method for treating a human patient diagnosed with cancer, comprising administering a therapeutically effective amount of a PRMT5 inhibitor, the method comprising: (i) administering at least about 0.1 mg (e.g., about 0.5 mg to about 5 mg, or about 0.5 mg to about 4 mg, or about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, or about 4.5 mg, or about 5 mg, etc.) of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)acetate per day; The method includes (i) administering to the patient an initial dose of a PRMT5 inhibitor, which is pentan-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial administration period of about 5 days to about 20 days (e.g., about 7 days to about 14 days); and (ii) administering to the patient at least about 0.1 mg (e.g., about 0.5 mg to about 5 mg, or about 0.5 mg to about 4 mg, or about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, or about 4 mg, or about 4.5 mg, or about 5 mg, etc.) of the PRMT5 inhibitor per day for one or more subsequent administration periods. In these methods, the first subsequent administration period can be spaced in time by at least about 5 days (e.g., about 7 days, or about 10 days, or about 14 days) from the first administration period, and the subsequent administration periods can be spaced in time by at least about 5 days (e.g., about 7 days, or about 10 days, or about 14 days) from each other.
[0054] In certain aspects, the disclosure provides a method for treating a human patient diagnosed with cancer, comprising administering a therapeutically effective amount of a PRMT5 inhibitor, the method comprising: (i) administering at least about 0.1 mg (e.g., about 0.5 mg to about 5 mg, or about 0.5 mg to about 4 mg, or about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, or about 4 mg, or about 4.5 mg, or about 5 mg, etc.) of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)silicate per day; (ii) administering to the patient an initial dose of a PRMT5 inhibitor, which is clopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial administration period of about 5 days to about 21 days (e.g., about 7 days to about 14 days); and (iii) administering to the patient at least about 0.1 mg (e.g., about 0.5 mg to about 5 mg, or about 0.5 mg to about 4 mg, or about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, or about 4 mg, or about 4.5 mg, or about 5 mg, etc.) of the PRMT5 inhibitor per day for one or more subsequent administration periods. In these methods, the first subsequent administration period can be spaced in time by at least about 5 days (e.g., about 7 days, or about 10 days, or about 14 days) from the first administration period, and the subsequent administration periods can be spaced in time by at least about 5 days (e.g., about 7 days, or about 10 days, or about 14 days) from each other.
[0055] In certain aspects, the disclosure provides a method for treating a human patient diagnosed with cancer, comprising administering a therapeutically effective amount of a PRMT5 inhibitor, the method comprising: (i) administering an initial dose of at least about 0.1 mg (e.g., about 0.5 mg to about 5 mg, or about 0.5 mg to about 4 mg, or about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, or about 4 mg, or about 4.5 mg, or about 5 mg, etc.) of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, per day for an initial dosing period of about 7 days to about 14 days (e.g., about 14 days). (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days to about 14 days (e.g., about 7 days); (ii) after the off period, administering at least about 0.1 mg (e.g., about 0.5 mg to about 5 mg, or about 0.5 mg to about 4 mg, or about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, or about 4 mg, or about 4.5 mg, or about 5 mg, etc.) of the PRMT5 inhibitor per day to the patient for a subsequent administration period of about 7 days to about 14 days (e.g., about 14 days); (iv) after the subsequent administration period, not administering the compound to the patient for an off period of about 7 days to about 14 days (e.g., about 7 days); and (v) optionally, continuously repeating steps (iii) and (iv). For example, step (v) may comprise consecutively repeating step (iii) and step (iv) at least 2 times, at least 4 times, at least 6 times, at least 8 times, at least 10 times, at least 12 times, at least 14 times, at least 16 times, at least 18 times, at least 20 times, at least 22 times, at least 24 times, etc.
[0056] As used herein, the term "subject" refers to an animal, preferably a mammal, such as a feline, canine, primate, or human, more preferably a human, i.e., a "human patient" or "human subject," who is the subject of treatment as described herein. In a preferred embodiment, a "human patient" or "human subject" is an adult human patient (i.e., a human aged 18 years or older).
[0057] As used herein, the term "treatment" is intended to refer to any process that can slow, hinder, inhibit, or halt the progression of a disease, although it does not necessarily indicate the complete disappearance of all symptoms.
[0058] As used herein, the term "compound of the disclosure" or "compound of the invention" refers to (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol of formula (I). This compound is also known as JNJ-64619178 and is described in WO 2017 / 032840, which is incorporated herein by reference.
[0059] [ka]
[0060] The compounds may also exist in tautomeric forms. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that are interconvertible via a low energy barrier. Such forms, to the extent they exist, are intended to be included within the scope of the present disclosure.
[0061] When the stereochemistry of any particular chiral atom is not specified in the structure shown herein, all stereoisomers are contemplated and included, either as pure stereoisomers or as mixtures of two or more stereoisomers.Therefore, the compounds described herein are meant to include stereoisomers and / or their tautomers.Therefore, the compounds of the present disclosure include all stereoisomers, such as enantiomers, atropisomers, or diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers, or mixtures thereof.
[0062] Also contemplated are salts of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol. Pharmaceutically acceptable salts include acid addition salts and base addition salts. Such salts can be formed by conventional means, for example, by reacting the free acid or free base form with one or more equivalents of a suitable acid or base, optionally in a solvent or medium in which the salt is insoluble, followed by removal of the solvent or medium using standard techniques (e.g., by vacuum, lyophilization or filtration). Salts can also be prepared by exchanging a counterion of a compound of the present disclosure in the form of a salt with another counterion, for example, using a suitable ion exchange resin.
[0063] Suitable acids include inorganic acids such as hydrohalic acids, for example, hydrochloric acid or hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or organic acids, for example, acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, oxalic acid (i.e., ethanedioic acid), malonic acid, succinic acid (i.e., butanedioic acid), maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclamic acid, salicylic acid, p-aminosalicylic acid, pamoic acid, and the like. Conversely, the above base forms can be converted to free base forms by treatment with an appropriate base. Compounds containing acidic protons or their solvates can be converted to their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases.
[0064] Suitable base salt forms include, for example, ammonium salts, alkali and alkaline earth metal salts such as lithium, sodium, potassium, magnesium, calcium salts, and the like, salts with organic bases such as primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline; benzathine, N-methyl-glucamine, hydrabamine salts, and salts with amino acids such as arginine, lysine, and the like. Conversely, the base forms can be converted to the free base forms by treatment with acid.
[0065] Additionally, prodrugs of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or salts thereof are contemplated. The term "prodrug" includes any compound that is metabolized in vivo to form the compound in experimentally detectable amounts. In some embodiments, prodrugs include compounds in which a hydroxyl, amino, sulfhydryl, carboxy, or carbonyl group in the compound is bonded to any group that can be cleaved in vivo to regenerate the free hydroxyl, amino, sulfhydryl, carboxy, or carbonyl group, respectively. Examples of prodrugs include, but are not limited to, esters and carbamates of hydroxy functional groups, ester groups of carboxy functional groups, N-acyl derivatives, and N-Mannich bases. General information regarding prodrugs can be found, for example, in Bundegaard, H. "Design of Prodrugs" p. 1-92, Elsevier, New York-Oxford (1985).
[0066] Also contemplated are solvates of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or its salts. As used herein, the term "solvates" includes hydrates and solvent addition forms that (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol can form, as well as pharma- ceutically acceptable addition salts thereof. Examples of such forms are, for example, hydrates, alcoholates, and the like. In some embodiments, a solvate of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol is used. In other embodiments, a hydrate of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol is used.
[0067] The general preparation of the compounds described herein is described in WO 2017 / 032840 and in the specific Examples and are generally prepared from starting materials that are commercially available or prepared by standard synthetic processes commonly used by those skilled in the art.
[0068] The methods described herein are useful for the treatment of cancer. The cancer may be a solid cancer or a cancer affecting the blood, i.e., a hematological cancer. As used herein, the term "solid cancer" refers to abnormal cell proliferation that may be present in a solid organ of a subject. In some embodiments, the cancer is characterized by a splicing factor mutation, such as myelodysplastic syndrome (MDS). In other embodiments, the cancer is a solid cancer. In other embodiments, the cancer is an advanced or refractory cancer. In other embodiments, the cancer is an advanced or refractory solid cancer. In one embodiment, the cancer is an advanced cancer. In one embodiment, the cancer is a refractory cancer. In a further embodiment, the cancer is a hematological cancer. The cancer may be hormone-dependent or hormone-independent. In one embodiment, the patient treated for cancer according to the present invention has previously undergone standard treatment options or is unsuitable for standard treatment options. In one embodiment, the patient treated for cancer according to the present invention has an Eastern Cooperative Oncology Group (ECOG) Performance Status score of grade 0 or 1 at the start of treatment.
[0069] The cancer may be at any stage in a subject. In some embodiments, the cancer is early or early stage, i.e., tumor ("T") stage, and the cancer is localized. In other embodiments, the cancer is advanced stage, i.e., advanced cancer. As used herein, the term "advanced stage" may refer to cancer that has spread to one or more regions of the body. Thus, in some aspects, the cancer has spread to lymph nodes and is an advanced cancer known as lymph node ("N") stage, e.g., lymph node positive ("N+") stage. In other aspects, the cancer has spread to other parts of the body and is an advanced cancer known as metastatic ("M") stage.
[0070] Examples of cancers that may be treated include acoustic neuroma, adenocarcinoma, adenoid cystic carcinoma (ACC), adrenal carcinoma, anal carcinoma, angiosarcoma, appendix carcinoma, benign monoclonal gammopathy, bile duct carcinoma, bladder carcinoma, breast cancer, brain cancer, bronchial carcinoma, carcinoid tumor, cervical cancer, chordoma, choriocarcinoma, craniopharyngioma, colorectal cancer, epithelial carcinoma, ependymoma, endothelio sarcoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, eye cancer, familial hypereosinophilia, gallbladder cancer, gastric cancer, gastrointestinal stromal tumor, head and neck cancer, hematopoietic cancer, heavy chain disease, hemangioblastoma, inflammatory myofibroblastic tumor, immunocytic amyloidosis, kidney cancer, liver cancer, lung cancer, leiomyosarcoma, mastocytosis, myelodysplastic syndromes (MDS, including low-risk MDS and high-risk MDS), mesothelioma, bone marrow cancer, and osteosarcoma. Proliferative disorders include, but are not limited to, neuroblastoma, neurofibroma, neuroendocrine carcinoma, osteosarcoma, ovarian cancer, papillary adenocarcinoma, parotid gland cancer, pancreatic cancer, penile cancer, pinealoma, primitive neuroectodermal tumor, prostate cancer, rectal cancer, rhabdomyosarcoma, salivary gland or ductal carcinoma, skin cancer, small intestine cancer, soft tissue sarcoma, sebaceous gland carcinoma, sweat gland carcinoma, synovial tumor, testicular cancer, thyroid cancer, urethral cancer, vaginal cancer, or vulvar cancer. In some embodiments, the cancer is salivary gland or ductal carcinoma, optionally salivary gland carcinoma. In some embodiments, the cancer is adenoid cystic carcinoma (ACC). In some embodiments, the cancer is lymphosarcoma, lymphangioendothelial sarcoma, or angiosarcoma, such as hemangio sarcoma. In other embodiments, the cancer is biliary cancer, such as cholangiocarcinoma. In a further embodiment, the cancer is breast cancer, such as breast adenocarcinoma, breast papillary carcinoma, mammary cancer, or medullary carcinoma of the breast. In yet a further embodiment, the breast cancer is triple negative carcinoma (TNBC). In yet another embodiment, the cancer is a brain tumor, such as a meningioma, glioma, or medulloblastoma. Examples of gliomas include astrocytoma or oligodendroglioma. In yet another embodiment, the cancer is a cervical cancer, such as a cervical adenocarcinoma. In another embodiment, the cancer is a colorectal cancer, such as a colon cancer, a rectal cancer, or a colorectal adenocarcinoma. In a further embodiment, the cancer is an endothelial sarcoma, such as Kaposi's sarcoma or multiple idiopathic hemorrhagic sarcoma. In yet another embodiment, the cancer is an endometrial cancer, such as a uterine cancer or a uterine sarcoma.In still further embodiments, the cancer is esophageal cancer, such as esophageal adenocarcinoma or Barrett's adenocarcinoma. In other embodiments, the cancer is ocular cancer, such as intraocular melanoma or retinoblastoma. In some aspects, the intraocular melanoma is uveal melanoma. In further embodiments, the cancer is gastric cancer, such as gastric adenocarcinoma. In yet other embodiments, the cancer is head and neck cancer, such as head and neck squamous cell carcinoma. In still further embodiments, the cancer is oral cancer, such as oral squamous cell carcinoma. In further embodiments, the cancer is parotid cancer. In other embodiments, the cancer is throat cancer, such as pharyngeal cancer, laryngeal cancer, nasopharyngeal cancer, or oropharyngeal cancer. In further embodiments, the cancer is hematopoietic cancer. Examples of hematopoietic cancer include leukemia, lymphoma, myeloproliferative neoplasms (MPN), and multiple myeloma. Examples of leukemia include acute lymphocytic leukemia, acute myelocytic leukemia, chronic myeloblastic leukemia, chronic myelomonocytic leukemia (CMML), or chronic lymphocytic leukemia. Examples of lymphoma include Hodgkin's lymphoma and non-Hodgkin's lymphoma (NHL). In some embodiments, the cancer is non-Hodgkin's lymphoma. In other examples, the cancer is MDS. In other embodiments, the cancer is low-risk MDS. In other embodiments, the cancer is low-risk MDS in patients who are red blood cell (RBC) transfusion dependent. In other embodiments, the cancer is low-risk MDS in patients who have relapsed or are refractory to erythropoietin stimulating agent (ESA) therapy. In other embodiments, the cancer is low-risk MDS in patients who are red blood cell (RBC) transfusion dependent and relapsed or are refractory to erythropoietin stimulating agent (ESA) therapy. In further embodiments, the cancer is multiple myeloma. In one embodiment, the cancer is breast cancer, prostate cancer, salivary duct carcinoma, adenoid cystic carcinoma, or uveal melanoma, hi another embodiment, the cancer is prostate cancer, salivary duct carcinoma, or adenoid cystic carcinoma (ACC).
[0071] Examples of lymphomas include B-cell NHL. Examples of acute lymphocytic leukemias include B-cell ALL and T-cell ALL. Examples of acute myeloid leukemias (AML) include B-cell AML or T-cell AML, such as low-risk AML and high-risk AML. Examples of chronic myeloid leukemias (CML) include B-cell CML or T-cell CML. Examples of chronic lymphocytic leukemias (CLL) include B-cell CLL or T-cell CLL. Examples of Hodgkin's lymphomas (HL) include B-cell HL and T-cell HL. Examples of non-Hodgkin's lymphomas (NHL) include B-cell NHL and T-cell NHL. Examples of B-cell NHL include diffuse large cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma, mantle cell lymphoma, marginal zone B-cell lymphoma, primary mediastinal B-cell lymphoma, Burkitt's lymphoma, lymphoplasmacytic lymphoma, immunoblastic large cell lymphoma, hairy cell leukemia, precursor B-lymphoblastic lymphoma, and primary central nervous system lymphoma; and T-cell NHL, such as precursor T-lymphoblastic lymphoma / leukemia, peripheral T-cell lymphoma, or multiple myeloma. In one embodiment, the B-cell NHL is diffuse large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma. Examples of diffuse large cell lymphoma include diffuse large B-cell lymphoma (DLBCL). Examples of peripheral T-cell lymphomas include cutaneous T-cell lymphoma, angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy-type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and anaplastic large cell lymphoma. Examples of cutaneous T-cell lymphomas, such as mycosis fungiodes or Sezary syndrome. Examples of marginal zone B-cell lymphomas include mucosa-associated lymphoid tissue lymphoma, nodal marginal zone B-cell lymphoma, or splenic marginal zone B-cell lymphoma. Examples of heavy chain diseases include alpha chain disease, gamma chain disease, or Mu chain disease. Examples of T-cell NHL include T-lymphoblastic lymphoma / leukemia, and peripheral T-cell lymphoma.
[0072] In yet other embodiments, the cancer is a heavy chain disease, such as an alpha chain disease, a gamma chain disease, or a Mu chain disease. In further embodiments, the cancer is a kidney cancer or renal cell carcinoma, such as nephroblastoma, i.e. Wilms' tumor. In still other embodiments, the cancer is a liver cancer, such as hepatocellular carcinoma or malignant hepatoma. In still further embodiments, the cancer is a lung cancer, such as bronchial carcinoma, non-small cell lung cancer (NSCLC), squamous cell lung carcinoma, lung adenocarcinoma, Lewis lung carcinoma, lung neuroendocrine tumor, typical carcinoid, atypical carcinoid, small cell lung carcinoma, or large cell neuroendocrine carcinoma. In some aspects, the cancer is small cell lung carcinoma (SCLC). In other embodiments, the cancer is a myeloproliferative disorder, such as polycythemia vera, essential thrombocythemia, primary myelofibrosis (also known as myelofibrosis (MF)), chronic idiopathic myelofibrosis, chronic myelogenous leukemia, chronic neutrophilic leukemia, or hypereosinophilic syndrome. In other embodiments, the cancer is a neurofibroma, such as neurofibromatosis type 1 or type 2, or schwannomatosis. In yet other embodiments, the cancer is a neuroendocrine carcinoma, such as a gastroenteropancreatic neuroendocrine tumor or a carcinoid tumor. In further embodiments, the cancer is an ovarian cancer, such as a cystadenocarcinoma, an ovarian embryonal carcinoma, or an ovarian adenocarcinoma. In other embodiments, the cancer is a pancreatic cancer, such as a pancreatic adenocarcinoma, an intraductal papillary mucinous tumor, or an islet cell tumor. In further embodiments, the cancer is a penile cancer, such as a Paget's disease of the penis and scrotum, a pinealoma, or a primitive neuroectodermal tumor. In yet other embodiments, the cancer is a prostate cancer, such as a prostate adenocarcinoma. In still further embodiments, the cancer is a skin cancer, such as a squamous cell carcinoma, a keratoacanthoma, a melanoma, or a basal cell carcinoma. In further embodiments, the cancer is a salivary gland cancer, such as a pleomorphic adenoma, a mucosal epithelioid carcinoma, and an acinar cell carcinoma. In other embodiments, the cancer is a small intestine cancer, such as an appendix cancer. In further embodiments, the cancer is a soft tissue sarcoma, such as malignant fibrous histiocytoma, liposarcoma, malignant peripheral nerve sheath tumor, chondrosarcoma, fibrosarcoma, or myxosarcoma. In yet other embodiments, the cancer is testicular cancer, such as seminoma or testicular embryonal carcinoma. In still further embodiments, the cancer is thyroid cancer, such as papillary carcinoma of the thyroid, papillary thyroid carcinoma, or medullary thyroid carcinoma. In other embodiments, the cancer is vulvar cancer, such as Paget's disease of the vulva. In further embodiments, the cancer is clear cell carcinoma, oncocytic carcinoma, or pleomorphic adenocarcinoma.
[0073] In some embodiments, the methods are useful for treating breast cancer, lung cancer, esophageal cancer, bladder cancer, hematopoietic cancer, lymphoma, medulloblastoma, rectal adenocarcinoma, colonic adenocarcinoma, gastric cancer, pancreatic cancer, liver cancer, adenoid cystic carcinoma, lung adenocarcinoma, head and neck squamous cell carcinoma (HNSCC), brain cancer, hepatocellular carcinoma, renal cell carcinoma, melanoma, oligodendroglioma, ovarian clear cell carcinoma, uveal melanoma, prostate cancer, and ovarian serous cystadenoma.
[0074] In other embodiments, the methods are useful for reducing the risk of cancer recurrence.
[0075] The methods described herein allow for the administration of PRMT5 inhibitors via any acceptable route. In some embodiments, the PRMT5 inhibitors are administered orally, parenterally (i.e., in the form of a liquid), rectally (i.e., in the form of a suppository), topically (i.e., in the form of a transdermal patch, ointment, or cream), or intranasally. Examples of parenteral administration include intravenous (IV) injection, intramuscular (IM) injection, and subcutaneous (SC) injection. Preferably, the PRMT5 inhibitors are administered orally. In other embodiments, the PRMT5 inhibitors are administered orally. In further embodiments, the PRMT5 inhibitors are administered parenterally. When administered orally, the PRMT5 inhibitors may be administered to subjects in a fed or fasted state. Preferably, the PRMT5 inhibitors are administered orally to subjects in a fasted state.
[0076] Although it is possible that the active ingredient is administered alone, i.e. undiluted, it may be present in a pharmaceutical composition.Therefore, the present disclosure further provides a pharmaceutical composition and, as an active ingredient, a PRMT5 inhibitor as described herein.The PRMT5 inhibitor may be formulated into various pharmaceutical forms for administration purposes.
[0077] When the PRMT5 inhibitor is formulated in a pharmaceutical composition, the composition also includes a pharma- ceutically acceptable carrier, diluent, and / or excipient. The particular carrier, diluent, and / or excipient will depend on the route of administration and can be determined by one skilled in the art. The carrier, diluent, and / or excipient must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof. Examples of excipients include diluents, lubricants, binders, and disintegrants, suspending agents, penetration enhancers, and / or suitable wetting agents. The excipient may be in the form of a liquid, such as water, glycol, oil, or alcohol, or a solid, such as starch, sugar, or kaolin.
[0078] Pharmaceutical compositions designed for oral administration may be in solid or liquid form. In some embodiments, the oral formulation is a liquid formulation, such as a suspension, syrup, elixir, emulsion, or solution. In other embodiments, the oral formulation is a solid formulation, such as a tablet (such as a split or coated tablet), a capsule, a caplet (such as a split or coated caplet), a pill, a powder, or a wafer. In one embodiment, the oral formulation is a capsule. In one embodiment, the oral formulation is a capsule containing 0.5 mg of a PRMT5 inhibitor (preferably (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof). In one embodiment, the oral formulation is a capsule containing 2 mg of a PRMT5 inhibitor (preferably, (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof).
[0079] To prepare pharmaceutical compositions, an effective amount of specific compound is combined with pharma- ceutically acceptable carrier as active ingredient.Carrier can be prepared with liquid solution, such as saline solution, glucose solution, oil, or mixtures thereof, such as mixtures of saline and glucose solution.Suitable oils include, but are not limited to, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, synthetic glycerol esters of long-chain fatty acids, and mixtures of these and other oils.
[0080] Compounds that may be suitable for treating or preventing cancer or cancer-related conditions can be administered alone or in combination with one or more additional therapeutic agents.Combination therapy includes administering a single pharmaceutical dosage formulation that contains the compound described herein, a pharmaceutically acceptable addition salt, or a solvate thereof, and one or more additional therapeutic agents, as well as administering the PRMT5 inhibitor and each additional therapeutic agent in its own separate pharmaceutical dosage formulation.For example, the PRMT5 inhibitor and the therapeutic agent can be administered to a patient together in a single oral dosage composition, such as a tablet or capsule, or each agent can be administered in a separate oral dosage formulation.
[0081] For use in the methods described herein, the compound may be administered in conjunction with adjuvant therapy. As used herein, the term "adjuvant therapy" refers to the administration of one or more other agents, more specifically other chemotherapy or techniques that may be used in cancer treatment. In some embodiments, the adjuvant therapy includes radiation. In some embodiments, the adjuvant therapy includes a chemotherapeutic agent. In further embodiments, the chemotherapeutic agent is a DNA methyltransferase inhibitor, such as 5-azaacytidine or decitabine. In yet other embodiments, the chemotherapeutic agent is 5-azaacytidine.
[0082] Embodiment Embodiment 1. A PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer by administration of a therapeutically effective amount of a PRMT5 inhibitor to the human patient, the administration comprising: (i) at least about 0.1 mg per day of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutical acceptable salt thereof; and (ii) administering to the patient an initial dose of the PRMT5 inhibitor, which is an acceptable addition salt or solvate thereof, over an initial administration period of about 5 to about 20 days; and (iii) administering to the patient subsequent doses of the PRMT5 inhibitor of at least about 0.1 mg per day over one or more subsequent administration periods of about 5 to about 20 days each, wherein a first subsequent administration period is separated in time by at least about 5 days from the initial administration period, and the subsequent administration periods are separated in time by at least about 5 days from each other.
[0083] Embodiment 2. A PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer, the method comprising administering to the human patient a therapeutically effective amount of a PRMT5 inhibitor, the method comprising: (i) administering at least about 0.1 mg per day of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutical formulation thereof; (ii) administering to the patient an initial dose of the PRMT5 inhibitor, which is a commercially acceptable addition salt or solvate thereof, over an initial administration period of about 5 to about 20 days, and (ii) administering to the patient a subsequent dose of at least about 0.1 mg of the PRMT5 inhibitor per day over one or more subsequent administration periods, each of which is about 5 to about 20 days, wherein the first subsequent administration period is separated in time by at least about 5 days from the initial administration period, and the subsequent administration periods are separated in time by at least about 5 days from each other.Embodiment 4. The PRMT5 inhibitor for use according to any one of embodiments 1-3, wherein each of the initial dose per day or each of the subsequent doses per day is independently at least about 0.5 mg, at least about 1 mg, at least about 2 mg, at least about 3 mg, at least about 4 mg, at least about 5 mg, at least about 5.5 mg, at least about 6 mg, at least about 8 mg, at least about 16 mg, at least about 30 mg, or at least about 60 mg.
[0084] Embodiment 5. A PRMT5 inhibitor for use according to any one of embodiments 1 to 4, wherein the initial daily dose or each of the subsequent daily doses is independently about 0.1 to about 100 mg, about 0.5 to about 80 mg, about 0.5 to about 60 mg, 0.5 to about 30 mg, about 0.5 to about 16 mg, about 0.5 to about 8 mg, about 0.5 to about 4 mg, about 0.5 to about 2 mg, or about 0.5 to about 1 mg.
[0085] Embodiment 6. A PRMT5 inhibitor for use according to any one of embodiments 1-5, wherein the first daily dose and each of the subsequent daily doses is independently about 0.5 mg, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 5.5 mg, about 6 mg, about 8 mg, about 12.5 mg, about 16 mg, about 25 mg, about 30 mg, about 50 mg, about 60 mg, about 100 mg, about 200 mg, about 400 mg, about 600 mg, about 800 mg, or about 1200 mg.
[0086] Embodiment 7. The PRMT5 inhibitor for use according to any one of embodiments 1 to 6, wherein the first dose or each of the at least one subsequent doses is administered once daily, or both the first dose and the at least one subsequent dose are administered once daily.
[0087] Embodiment 8. The PRMT5 inhibitor for use according to any one of embodiments 1-7, wherein the first dose or each of the at least one subsequent dose is administered in a divided dose twice daily (BID), or both the first dose and the at least one subsequent dose are administered in a divided dose twice daily.
[0088] Embodiment 9. A PRMT5 inhibitor for use according to embodiment 8, wherein the divided doses are equal.
[0089] Embodiment 10. A PRMT5 inhibitor for use according to any one of embodiments 1 to 9, wherein the initial administration period is from about 7 days to about 14 days.
[0090] Embodiment 11. The PRMT5 inhibitor for use according to any one of embodiments 1 to 10, wherein the initial administration period is about 7 days.
[0091] Embodiment 12. The PRMT5 inhibitor for use according to any one of embodiments 1 to 11, wherein the initial administration period is about 14 days.
[0092] Embodiment 13. The PRMT5 inhibitor for use according to any one of embodiments 1 to 12, wherein the first subsequent administration period is spaced in time from the first administration period by at least about 7 days, and the subsequent administration periods are spaced in time from each other by at least about 7 days.
[0093] Embodiment 14. The PRMT5 inhibitor for use according to any one of embodiments 1 to 13, wherein the first subsequent administration period is spaced in time from the first administration period by about 7 days, and the subsequent administration periods are spaced in time from each other by about 7 days.
[0094] Embodiment 15. A PRMT5 inhibitor for use according to any one of embodiments 1 to 12, wherein each subsequent administration period is from about 7 days to about 14 days.
[0095] Embodiment 16. A PRMT5 inhibitor for use according to any one of embodiments 1 to 15, wherein each subsequent administration period is about 7 days.
[0096] Embodiment 17. A PRMT5 inhibitor for use according to any one of embodiments 1 to 15, wherein each subsequent administration period is about 14 days.
[0097] Embodiment 18. A PRMT5 inhibitor for use according to any one of embodiments 1 to 17, wherein the first dose or at least one subsequent dose is administered orally, or the first dose and at least one subsequent dose are administered orally.
[0098] Embodiment 19. The PRMT5 inhibitor for use according to any one of embodiments 1 to 18, wherein the initial dose and at least one subsequent dose are identical.
[0099] Embodiment 20. A PRMT5 inhibitor for use according to any one of embodiments 1 to 18, wherein the initial dose and at least one subsequent dose are different.
[0100] Embodiment 21. The PRMT5 inhibitor for use according to any one of embodiments 1 to 20, wherein the cancer is an advanced cancer.
[0101] In embodiment 22, the cancer is selected from the group consisting of acoustic neuroma, adenocarcinoma, adenoid cystic carcinoma, adrenal carcinoma, anal carcinoma, angiosarcoma, appendix carcinoma, benign monoclonal gammopathy, bile duct carcinoma, bladder carcinoma, breast cancer, brain tumor, bronchial carcinoma, carcinoid tumor, cervical carcinoma, chordoma, choriocarcinoma, craniopharyngioma, colorectal carcinoma, epithelial carcinoma, ependymoma, endothelial sarcoma, endometrial carcinoma, esophageal carcinoma, Ewing's sarcoma, eye cancer, familial hypereosinophilia, gallbladder carcinoma, gastric cancer, gastrointestinal stromal tumor, head and neck cancer, hematopoietic cancer, heavy chain disease, hemangioblastoma, inflammatory myofibroblastic tumor, immunocytic ami 22. The PRMT5 inhibitor for use according to any one of embodiments 1 to 21, wherein the cancer is selected from the group consisting of myeloma, pulmonary myeloma, myelodysplastic syndrome, renal cancer, liver cancer, lung cancer, leiomyosarcoma, mastocytosis, myelodysplastic syndrome, mesothelioma, myeloproliferative disorder, neuroblastoma, neurofibroma, neuroendocrine carcinoma, osteosarcoma, ovarian cancer, papillary adenocarcinoma, pancreatic cancer, penile cancer, pinealoma, primitive neuroectodermal tumor, prostate cancer, rectal cancer, rhabdomyosarcoma, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, sebaceous gland carcinoma, sweat gland carcinoma, synovial tumor, testicular cancer, thyroid cancer, urethral cancer, vaginal cancer, or vulvar cancer.
[0102] Embodiment 23. A PRMT5 inhibitor for use according to any one of embodiments 1 to 22, wherein the cancer is a solid tumor.
[0103] Embodiment 24. The PRMT5 inhibitor for use according to any one of embodiments 1 to 23, wherein the cancer is non-small cell lung cancer.
[0104] Embodiment 25. The PRMT5 inhibitor for use according to any one of embodiments 1 to 22, wherein the cancer is a hematopoietic cancer.
[0105] Embodiment 26 The PRMT5 inhibitor for use according to embodiment 25, wherein the cancer is non-Hodgkin's lymphoma.
[0106] Embodiment 27. A PRMT5 inhibitor for use according to any one of embodiments 1 to 26, further comprising administering to the patient an adjuvant therapy.
[0107] Embodiment 28. The PRMT5 inhibitor for use according to embodiment 27, wherein the adjuvant therapy comprises administering radiation to the patient.
[0108] Embodiment 29. The PRMT5 inhibitor for use according to embodiment 27, wherein the adjuvant therapy comprises administering to the patient an effective amount of a chemotherapeutic agent.
[0109] Embodiment 30. A PRMT5 inhibitor for use according to embodiment 29, wherein the chemotherapeutic agent is a DNA methyltransferase inhibitor such as 5-azacytidine or decitabine, preferably 5-azacytidine.
[0110] Embodiment 31. A PRMT5 inhibitor for use according to any one of embodiments 1 to 30, wherein efficacy is measured by determining the patient's time to disease progression or patient response rate.
[0111] Embodiment 32. A PRMT5 inhibitor for use according to any one of embodiments 1 to 31, wherein the compound is a pharma- ceutically acceptable addition salt of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol.
[0112] Embodiment 33. A PRMT5 inhibitor for use according to any one of embodiments 1 to 32, wherein the compound is a solvate of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol.
[0113] Embodiment 34. The PRMT5 inhibitor for use according to embodiment 33, wherein the solvate is a hydrate.
[0114] Embodiment 35. A PRMT5 inhibitor for use according to any one of embodiments 1 to 32, wherein the compound is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol.
[0115] Embodiment 36. A method for treating a human patient diagnosed with cancer by administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor to the human patient, the administration comprising: (i) administering to the patient an initial dose of about 0.1 mg to about 5 mg per day of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial administration period of about 14 days; (ii) administering to the patient a subsequent dose of about 0.1 mg to about 5 mg of a PRMT5 inhibitor per day for one or more subsequent dosing periods; During the ceremony, the first subsequent dosing period is separated in time by at least about 7 days from the first dosing period; The subsequent administration periods are separated in time by at least about 7 days from each other.
[0116] Embodiment 37. A method for treating a human patient diagnosed with cancer by administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor to the human patient, the administration comprising: (i) administering to the patient an initial dose of at least about 0.1 mg per day of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 7 days to about 14 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days to about 14 days; (iii) administering to the patient after the off period a subsequent dose of at least about 0.1 mg of a PRMT5 inhibitor per day for a subsequent dosing period of about 7 days to about 14 days; (iv) after the subsequent administration period, the compound is not administered to the patient for an off period of about 7 days to about 14 days. (v) optionally repeating steps (iii) and (iv) successively.
[0117] 38. (i) administering to the patient an initial dose of at least about 0.1 mg per day of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 14 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days; and (iii) after the off period, administering to the patient a subsequent dose of at least about 0.1 mg of a PRMT5 inhibitor per day for a subsequent dosing period of about 14 days; (iv) after the subsequent administration period, the compound is not administered to the patient for an off period of about 7 days; and (v) optionally repeating steps (iii) and (iv) successively.
[0118] 39. (i) administering to the patient an initial dose of at least about 0.1 mg per day of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 7 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days; and (iii) after the off period, administering to the patient a subsequent dose of at least about 0.1 mg of a PRMT5 inhibitor per day for a subsequent dosing period of about 7 days; (iv) after the subsequent administration period, the compound is not administered to the patient for an off period of about 7 days; and (v) optionally repeating steps (iii) and (iv) successively.
[0119] Embodiment 40. The PRMT5 inhibitor for use according to any one of embodiments 37 to 39, wherein step (v) comprises repeating steps (iii) and (iv) consecutively at least four times.
[0120] Embodiment 41. A PRMT5 inhibitor for use according to any one of embodiments 37 to 40, comprising administering to the patient an initial dose of from about 0.5 mg to about 5 mg of the PRMT5 inhibitor per day, and administering to the patient subsequent doses of from about 0.5 mg to about 5 mg of the PRMT5 inhibitor per day.
[0121] Embodiment 42. A PRMT5 inhibitor for use according to any one of embodiments 37 to 41, wherein the method is effective to reduce tumor volume in a patient.
[0122] Aspects Embodiment 1. A method for treating a human patient diagnosed with cancer comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, (i) administering to the patient an initial dose of at least about 0.1 mg per day of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 5 to about 20 days; (ii) administering to the patient subsequent doses of at least about 0.1 mg of a PRMT5 inhibitor per day for one or more subsequent dosing periods, each of about 5 to about 20 days; During the ceremony, the first subsequent dosing period is separated in time by at least about 5 days from the first dosing period; The subsequent administration periods are separated in time by at least about 5 days from each other.
[0123] Aspect 3. The method of aspect 1, wherein the first dose per day or each subsequent dose per day is independently at least about 0.5 mg, at least about 1 mg, at least about 2 mg, at least about 3 mg, at least about 4 mg, at least about 5 mg, at least about 5.5 mg, at least about 6 mg, at least about 8 mg, at least about 16 mg, at least about 30 mg, or at least about 60 mg.
[0124] Aspect 4. The method of any one of Aspects 1 to 3, wherein the initial dose per day or each of the subsequent doses per day is independently about 0.1 to about 100 mg, about 0.5 to about 80 mg, about 0.5 to about 60 mg, 0.5 to about 30 mg, about 0.5 to about 16 mg, about 0.5 to about 8 mg, about 0.5 to about 4 mg, about 0.5 to about 2 mg, or about 0.5 to about 1 mg.
[0125] Aspect 5. The method of any one of aspects 1-4, wherein the first dose per day and each of the subsequent doses per day are independently about 0.5 mg, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 5.5 mg, about 6 mg, about 8 mg, about 12.5 mg, about 16 mg, about 25 mg, about 30 mg, about 50 mg, about 60 mg, about 100 mg, about 200 mg, about 400 mg, about 600 mg, about 800 mg, or about 1200 mg.
[0126] Embodiment 6. The method of any one of embodiments 1-5, wherein the first dose or each of the at least one subsequent dose is administered once daily, or both the first dose and the at least one subsequent dose are administered once daily.
[0127] Embodiment 7. The method of any one of embodiments 1-5, wherein the first dose or each of the at least one subsequent dose is administered in a split dose twice daily (BID), or wherein both the first dose and the at least one subsequent dose are administered in a split dose twice daily.
[0128] Embodiment 8. The method of embodiment 7, wherein the divided doses are equal.
[0129] Aspect 9. The method according to any one of Aspects 1 to 8, wherein the initial administration period is from about 7 days to about 14 days.
[0130] Aspect 10. The method of any one of aspects 1 to 9, wherein the initial administration period is about 7 days.
[0131] Embodiment 11. The method of any one of embodiments 1 to 9, wherein the initial administration period is about 14 days.
[0132] Embodiment 12. The method of any one of embodiments 1-11, wherein the first subsequent administration period is spaced in time from the first administration period by at least about 7 days, and the subsequent administration periods are spaced in time from each other by at least about 7 days.
[0133] Aspect 13. The method of any one of aspects 1-12, wherein the first subsequent administration period is spaced in time from the first administration period by about 7 days, and the subsequent administration periods are spaced in time from each other by about 7 days.
[0134] Aspect 14. The method of any one of aspects 1 to 11, wherein each subsequent administration period is from about 7 days to about 14 days.
[0135] Embodiment 15. The method of any one of embodiments 1 to 14, wherein each subsequent administration period is about 7 days.
[0136] Embodiment 16 The method of any one of embodiments 1 to 14, wherein each subsequent administration period is about 14 days.
[0137] Embodiment 17. The method according to any one of embodiments 1 to 16, wherein the first dose or at least one subsequent dose is administered orally, or the first dose and at least one subsequent dose are administered orally.
[0138] Embodiment 18. The method according to any one of embodiments 1 to 17, wherein the initial dose and at least one subsequent dose are the same.
[0139] Embodiment 19. The method according to any one of embodiments 1 to 17, wherein the initial dose and at least one subsequent dose are different.
[0140] Embodiment 20. The method according to any one of embodiments 1 to 19, wherein the cancer is an advanced cancer.
[0141] Aspect 21. The cancer is selected from the group consisting of acoustic neuroma, adenocarcinoma, adenoid cystic carcinoma, adrenal cancer, anal cancer, angiosarcoma, appendix cancer, benign monoclonal gammopathy, bile duct cancer, bladder cancer, breast cancer, brain tumor, bronchial cancer, carcinoid tumor, cervical cancer, chordoma, choriocarcinoma, craniopharyngioma, colorectal cancer, epithelial cancer, ependymoma, endothelial sarcoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, eye cancer, familial hypereosinophilia, gallbladder cancer, gastric cancer, gastrointestinal stromal tumor, head and neck cancer, hematopoietic cancer, heavy chain disease, hemangioblastoma, inflammatory myofibroblastic tumor, immune 21. The method of any one of aspects 1 to 20, wherein the cancer is myeloid cytosis, renal cancer, liver cancer, lung cancer, leiomyosarcoma, mastocytosis, myelodysplastic syndrome, mesothelioma, myeloproliferative disorder, neuroblastoma, neurofibroma, neuroendocrine carcinoma, osteosarcoma, ovarian cancer, papillary adenocarcinoma, pancreatic cancer, penile cancer, pinealoma, undifferentiated neuroectodermal tumor, prostate cancer, rectal cancer, rhabdomyosarcoma, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, sebaceous gland carcinoma, sweat gland carcinoma, synovial tumor, testicular cancer, thyroid cancer, urethral cancer, vaginal cancer, or vulvar cancer.
[0142] Embodiment 22. The method of any one of embodiments 1 to 21, wherein the cancer is a solid tumor.
[0143] Embodiment 23. The method according to any one of embodiments 1 to 22, wherein the cancer is non-small cell lung cancer.
[0144] Embodiment 24. The method according to any one of embodiments 1 to 21, wherein the cancer is a hematopoietic cancer.
[0145] Embodiment 25 The method of embodiment 24, wherein the cancer is non-Hodgkin's lymphoma.
[0146] Embodiment 26 The method according to any one of embodiments 1 to 25, further comprising administering an adjuvant therapy to the patient.
[0147] The method of embodiment 26, wherein the adjuvant therapy comprises administering radiation to the patient.
[0148] Embodiment 28 The method of embodiment 26, wherein the adjuvant therapy comprises administering to the patient an effective amount of a chemotherapeutic agent.
[0149] Embodiment 29. The method according to embodiment 28, wherein the chemotherapeutic agent is a DNA methyltransferase inhibitor, such as 5-azacytidine or decitabine, preferably 5-azacytidine.
[0150] Aspect 30. The method of any one of aspects 1 to 29, wherein efficacy is measured by determining the patient's time to disease progression or patient response rate.
[0151] Aspect 31. The method of any one of aspects 1 to 30, wherein the compound is a pharma- ceutically acceptable addition salt of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol.
[0152] Aspect 32. The method of any one of aspects 1 to 31, wherein the compound is a solvate of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol.
[0153] Embodiment 33. The method of embodiment 32, wherein the solvate is a hydrate.
[0154] Embodiment 34. The method of any one of embodiments 1 to 31, wherein the compound is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol.
[0155] 35. A method for treating a human patient diagnosed with cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, (i) administering to the patient an initial dose of about 0.1 mg to about 5 mg per day of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial administration period of about 14 days; (ii) administering to the patient a subsequent dose of about 0.1 mg to about 5 mg of a PRMT5 inhibitor per day for one or more subsequent dosing periods; During the ceremony, the first subsequent dosing period is separated in time by at least about 7 days from the first dosing period; The subsequent administration periods are separated in time by at least about 7 days from each other.
[0156] 36. A method for treating a human patient diagnosed with cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, (i) administering to the patient an initial dose of at least about 0.1 mg per day of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 7 days to about 14 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days to about 14 days; (iii) administering to the patient after the off period a subsequent dose of at least about 0.1 mg of a PRMT5 inhibitor per day for a subsequent dosing period of about 7 days to about 14 days; (iv) after the subsequent administration period, the compound is not administered to the patient for an off period of about 7 days to about 14 days. (v) optionally repeating steps (iii) and (iv) successively.
[0157] Aspect 37. (i) administering to the patient an initial dose of at least about 0.1 mg per day of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 14 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days; and (iii) after the off period, administering to the patient a subsequent dose of at least about 0.1 mg of a PRMT5 inhibitor per day for a subsequent dosing period of about 14 days; (iv) after the subsequent administration period, the compound is not administered to the patient for an off period of about 7 days; and (v) optionally repeating steps (iii) and (iv) continuously.
[0158] Aspect 38. (i) administering to the patient an initial dose of at least about 0.1 mg per day of a PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 7 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days; and (iii) after the off period, administering to the patient a subsequent dose of at least about 0.1 mg of a PRMT5 inhibitor per day for a subsequent dosing period of about 7 days; (iv) after the subsequent administration period, the compound is not administered to the patient for an off period of about 7 days; and (v) optionally repeating steps (iii) and (iv) continuously.
[0159] Embodiment 39. The method of any one of embodiments 36 to 38, wherein step (v) comprises repeating steps (iii) and (iv) at least four times in succession.
[0160] Embodiment 40. The method of any one of embodiments 36 to 39, comprising administering to the patient an initial dose of from about 0.5 mg to about 5 mg of the PRMT5 inhibitor per day, and administering to the patient subsequent doses of from about 0.5 mg to about 5 mg of the PRMT5 inhibitor per day.
[0161] Embodiment 41. The method according to any one of embodiments 36 to 40, wherein the method is effective to reduce tumor volume in the patient.
[0162] [Table 2-1]
[0163] [Table 2-2] EXAMPLES
[0164] Example 1. Drug Substance The JNJ-64619178 drug substance administered in the in vivo mouse studies and human clinical trials described herein has a molecular weight of 483.37, C 22 H 23 It has the molecular formula of BrNO2 and the chemical name (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol. The drug substance was prepared and characterized as described in WO 2017 / 032840, which is incorporated herein by reference.
[0165] Example 2. Formulation The JNJ-64619178 drug substance supplied for the clinical trials described herein was formulated as 0.5 mg and 2 mg capsules for oral administration. In addition to the drug substance, each capsule contains colloidal silicon dioxide as a flow agent and a hard gelatin capsule shell (size 0 for the 0.5 mg capsule and size 3 for the 2.0 mg capsule, each capsule shell containing, e.g., gelatin and titanium dioxide).
[0166] Example 3. In vivo lung cancer model: Efficacy of JNJ-64619178 in an established NCI-H1048 SCLC model A. Clinical Trial 1 JNJ-64619178 was tested for antitumor activity in the NCI-H1048 human xenograft model of SCLC. Male mice were implanted with NCI-H1048 cells subcutaneously and tumors were allowed to grow for 14 days. At the start of treatment, tumor volume was 174 ± 51 mm. 3 Mice were orally dosed once daily with 1, 3, and 10 mg / kg JNJ-64619178 or 20% hydroxypropyl-β-cyclodextrin (HP-β-CD) vehicle control for up to 28 days.
[0167] JNJ-64619178 demonstrated biologically significant antitumor activity at 3 and 10 mg / kg. At the 10 mg / kg dose, JNJ-64619178 induced complete tumor responses that were maintained for up to 14 days after dosing. Group mean tumor volumes are shown in Figure 2. Compared to vehicle controls, there was statistically significant antitumor activity at 1, 3, and 10 mg / kg doses of JNJ-64619178, with 10 mg / kg achieving 99.1% tumor growth inhibition (TGI) at 42 days after implantation.
[0168] These results were confirmed in a second human SCLC mouse xenograft trial. Mice bearing NCI H1048 human SCLC xenografts were treated by oral gavage with JNJ-64619178 (1, 3, and 10 mg / kg) or 20% HP β CD vehicle control for 10 days and observed for tumor regrowth for an additional 10 days. Biologically significant TGI (up to 72.9%) was observed with 10 mg / kg JNJ 64619178 and continued for several days during the post-dose period.
[0169] Figure 1 details the individual tumor regrowth observed after cessation of once-daily treatment with 10 mg / kg JNJ 64619178 or vehicle control. In all eight mice treated with 10 mg / kg JNJ 64619178, tumor regrowth began 14 days after cessation of treatment, and tumors reached ethical limits by day 92 after implantation.
[0170] B. Clinical Trial 2 NCI-H1048 lung cancer xenografted mice were orally administered JNJ-64619178 (10 mg / kg) for 9 consecutive days, followed by cessation of treatment for 11 days. Tumors (n=3 nude mice / group) were harvested 2 h after dosing (days 0, 1, 2, 3, and 6) and every day after cessation of treatment, and concentrations of SmD1 / 3-Me2 were assessed by immunoblotting and normalized to the median β-actin protein concentration measured from vehicle (20% HP-β-CD) treated tumor samples. The percentage (%) of SmD1 / 3-Me2 concentration compared to the vehicle treated group (defined as 100%) is visualized in Figure 3 as a box plot with whiskers from minimum to maximum values, and the median values are connected by a line. The grey shaded area represents the dosing period, and the dotted bars represent the concentration of SmD1 / 3-Me2 in untreated samples.
[0171] C. Clinical Trial 3 Mice bearing NCI-H1048 xenografts (n=8 mice / group) were orally administered vehicle (20% HP-β-CD) or JNJ-64619178 (10 mg / kg) once daily for either 28 consecutive days or two cycles of 7-day daily drug treatment followed by a 7-day rest period (7+ / 7-, 2 cycles), and tumor growth inhibition (TGI, %) relative to vehicle treatment was calculated on day 28, which was 62% and 63%, respectively. In all xenograft trials, the mean tumor volume at the start of treatment was approximately 150 mm 3 and the mean tumor volume (mm 3 )±SEM was graphed over time as shown in FIG.
[0172] Example 4. A Phase I, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178 in Subjects with Advanced Cancer This is a multipart, Phase 1, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of JNJ-64619178 monotherapy administered to either adult human subjects with advanced solid tumors or B-cell non-Hodgkin's lymphoma who have previously received or are unsuitable for standard treatment options, or adult subjects with lower-risk myelodysplastic syndromes (MDS) who are red blood cell (RBC) transfusion dependent and relapsed or refractory to erythropoietin-stimulating agent (ESA) treatment.
[0173] Initial clinical results In the "Phase 1" study described below, 15 participants with various solid tumors (e.g., breast cancer, prostate cancer, salivary duct carcinoma, adenoid cystic carcinoma) were administered 0.5 mg (group 1), 1 mg (group 2), 2 mg (group 3), and 4 mg (group 4) of JNJ-64619178 on a 14-day continuous infusion schedule followed by a 7-day rest period (14 days on / 7 days off in a 21-day cycle). The mean treatment duration ranged from 4 weeks (4 mg, 14 days on / 7 days off) to 6 months (1 mg, 14 days on / 7 days off) in group 2. The most frequently reported adverse events (AEs) in the first three groups were hematological, gastrointestinal, and dermatological. Non-hematologic toxicities were grade 1 or 2, except for one case of grade 3 in which vomiting lasted 24 hours. No dose-limiting toxicities (DLTs) were observed in the first three groups. The first part of the trial is ongoing.
[0174] Subsequent clinical results In the "Part 1" study described below, 54 participants with a variety of solid tumors (e.g., breast cancer, prostate cancer, salivary ductal carcinoma, adenoid cystic carcinoma, and uveal melanoma) were administered JNJ-64619178 at 0.5 mg (Group 1), 1 mg (Group 2), 2 mg (Group 3), 4 mg (Group 4), and 3 mg (Group 5) on a 14-day continuous infusion schedule followed by a 7-day rest period (14 days on / 7 days off in a 21-day cycle), or at 1 mg (Group 6) or 2 mg (Group 7) on a 21-day continuous infusion schedule. The mean treatment duration was 3 months, ranging from 0.4 to 22.4 months. Adverse events (AEs) observed in less than 20% of participants were gastrointestinal disorders (nausea, vomiting, diarrhea), hematological disorders (thrombocytopenia, anemia, neutropenia), general disorders (fatigue and asthenia), and dysgeusia. In groups 4, 5, and 6, dose-limiting toxicities of grade 4 or grade 3 thrombocytopenia lasting longer than 7 days were observed. The maximum tolerated dose was considered to be 3 mg on a 14-day on / 7-day off schedule or 2 mg on a continuous infusion schedule. Of the 45 participants evaluable for efficacy, 1 (4.3%), 24 (52%), and 20 (43%) had confirmed best overall response rates of partial response, stable disease, and progressive disease, respectively. Participants with confirmed PR were participants in group 2.
[0175] JNJ64619178 Plasma C max and AUC were linearly proportional to dose. Robust target engagement was achieved even with intermittent dosing, as measured by plasma SDMA. Confirmed partial responses (RECIST) were observed in ACC, and patients with ACC, prostate cancer, salivary duct carcinoma, and other tumor types had stable disease for >6 months. Two tentative RP2Ds were selected: 1.5 mg intermittent and 1 mg QD.
[0176] This data indicates that JNJ64619178 demonstrated manageable toxicity and preliminary evidence of antitumor activity at the selected dose levels. Intermittent dosing also maintained target inhibition.
[0177] Further clinical trials for Parts 1 and 2 are described below.
[0178] Clinical Protocol
[0179] [Table 3]
[0180] Subject population For purposes of this example, eligible subjects must be 18 years of age or older, have relapsed or refractory B-cell NHL (diffuse large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma), RBC transfusion-dependent and ESA-relapsed or refractory lower-risk MDS, or progressive or refractory solid tumors, have documented histology of disease, at least one measurable site of disease for solid tumors and NHL, an Eastern Cooperative Oncology Group (ECOG) Performance Status score of grade 0 or 1, and laboratory and cardiac parameters within the study-specified criteria for enrollment.
[0181] Dosage and Administration The starting dose of JNJ-64619178 was based on toxicological results obtained using the no observed adverse effect level (NOAEL) dose, which is more conservative than the highest dose not causing severe toxicity in dogs (HNSTD) as the most sensitive species. A default safety factor of 6 (used for non-rodent HNSTD) was used to obtain a starting dose of 0.54 mg once daily (QD), which was rounded to 0.5 mg QD. A single dose of study drug was administered during the pharmacokinetic run-in phase of Part 1. During the treatment phase, study drug was administered in a 21-day cycle with 14 days of continuous dosing followed by 7 days of rest (14 days on / 7 days off dosing). Alternative dosing schedules (e.g., continuous dosing, 7 days on / 7 days off, and 7 days on / 14 days off) were also evaluated.
[0182] The study began with dosing schedule A (14 days on / 7 days off in a 21 day cycle). Table B below provides examples of possible dose escalations. A summary of study drug dosing is provided in Table C.
[0183] [Table 4]
[0184] [Table 5]
[0185] The study drug administration schedule is shown in Table D.
[0186] [Table 6]
[0187] The study will be divided into two parts, with up to four periods: screening, pharmacokinetic run-in, treatment, and post-treatment follow-up. The study drug dosing schedule is shown in Table D above.
[0188] Pharmacokinetics Introductory Phase The pharmacokinetic run-in phase will evaluate the pharmacokinetics of a single dose of JNJ64619178 prior to administration of subsequent daily doses in the treatment phase. Subjects will receive a single dose of study drug at the site on Day 1 and remain at the site for at least 6 hours for pharmacokinetic assessment. The single dose of study drug will be followed by a 6-day rest period (i.e., Days 2-7 [range 5-10 days is allowed]) for collection of pharmacokinetic blood samples and ECGs. Certain subjects in Part 1 may not participate in the pharmacokinetic run-in phase.
[0189] Treatment Phase The treatment phase begins with administration of study drug on Day 1 of Cycle 1 and continues until completion of the end-of-treatment visit. During the treatment phase, the pharmacokinetics of multiple doses of JNJ-64619178 will be evaluated. On Day 14 of Cycle 1, Part 1 subjects will remain at the site for at least 8 hours after study drug administration for pharmacokinetic and ECG evaluations. Study drug should be administered at approximately the same time each day to accurately assess the pharmacokinetics of JNJ 64619178.
[0190] Subjects will visit on Day 1 of each cycle for administration of study drug and will receive sufficient study drug to self-administer at home. Diary cards will be provided to record study drug intake at home. Instructions regarding self-administration at home will be reinforced at each visit. Subjects will also be evaluated at each visit for possible toxicities.
[0191] Investigational drug may be administered until disease progression (according to disease-specific criteria) or until one of the investigational drug discontinuation criteria is met. Part 2 subjects will receive treatment for a minimum of 24 weeks unless they have previously met a study discontinuation criterion. Subjects with evidence of clinical benefit may continue on investigational drug until disease progression or loss of hematologic response. Upon discontinuation of investigational drug, subjects will complete an EOT visit.
[0192] Reporting Adverse Events (i) Adverse Event: An adverse event is any untoward medical occurrence in a clinical trial subject administered a medicinal product (investigational or non-investigational medicinal product). An adverse event does not necessarily have a causal relationship to the investigational medicinal product. Thus, an adverse event can be any untoward, unintended sign (e.g., abnormal clinical laboratory value), symptom, or disease that is temporally related to the use of a medicinal product (investigational or non-investigational medicinal product), whether or not it has a causal relationship to the medicinal product (investigational or non-investigational medicinal product). (Definition by the International Conference on Harmonisation (ICH). This includes any occurrence that is new onset or a worsening in severity or frequency from a baseline condition, or an abnormal result of a diagnostic procedure, including an abnormal laboratory test.
[0193] (ii) Serious Adverse Event: A serious adverse event according to the ICH and EU Guidelines on Pharmacovigilance for Medicinal Products for Human Use is any untoward medical occurrence regardless of dose as follows: -Causes death Life-threatening (Subject was in danger of death at the time of the event; it does not mean that the event would have been fatal if it had been more severe.) -Necessitating hospitalization or an extension of an existing hospital stay Leading to permanent or serious impairment / incapacity ·Causes birth defects / abnormalities - Suspected transmission of any infectious agent via medicinal products Medically significant * *Medical and scientific judgment should be exercised in determining whether expedited reporting is appropriate in other situations, such as significant medical events that, although not immediately life-threatening or resulting in death or hospitalization, may endanger the subject or require intervention to prevent one of the other outcomes listed in the definition above. These should normally be considered serious.
[0194] Undescribed (unanticipated) adverse events / safety information An adverse event is considered undescribed if its nature or severity is inconsistent with the applicable product reference safety information.
[0195] Adverse events related to the use of the investigational drug If a causal relationship is considered likely and highly probable or extremely likely, the adverse event is considered to be related to the investigational use.
[0196] (iii) Attribution definition Unrelated: Adverse events not related to the use of the investigational drug.
[0197] Doubtful: Adverse events where alternative explanations are more likely, e.g., concomitant medications, comorbidities, or time relationships, suggest that a causal relationship is unlikely.
[0198] Possible: Adverse event that may be attributable to the use of the therapeutic agent. Alternative explanations, e.g., concomitant medications, comorbidities, are inconclusive. The time relationship is reasonable and therefore a causal relationship cannot be excluded.
[0199] High probability: Adverse event that can be attributed to the use of the investigational drug. A time relationship is implicit (e.g., confirmed by drug discontinuation). Alternative explanations, e.g., concomitant medications, comorbidities, are unlikely.
[0200] Very High: The adverse event is listed as a possible adverse reaction and cannot be reasonably explained by alternative explanations (e.g., concomitant medications, comorbidities). The time relationship is highly suggestive (e.g., confirmed by interruption and resumption of drug administration).
[0201] (iv) Severity criteria Severity grading will be done according to NCI CTCAE Version 4.03. See Table E.
[0202] [Table 7] The present invention includes the following aspects. <1> 1. A PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer, comprising administering to said human patient a therapeutically effective amount of said PRMT5 inhibitor, said administering comprising: (i) administering to the patient an initial dose of at least about 0.1 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 5 to about 21 days; (ii) administering to the patient subsequent doses of at least about 0.1 mg of the PRMT5 inhibitor per day for one or more subsequent dosing periods, each of about 5 to about 21 days; the first subsequent administration period is separated in time by at least about 5 days from said first administration period; The subsequent administration periods are separated in time from each other by at least about 5 days. <2> the cancer is characterized by a splicing factor mutation; <1> The PRMT5 inhibitor according to claim 1. <3> wherein said initial dose per day or each of said subsequent doses per day is independently at least about 0.5 mg, at least about 1 mg, at least about 1.5 mg, at least about 2 mg, at least about 3 mg, at least about 4 mg, at least about 5 mg, at least about 5.5 mg, at least about 6 mg, at least about 8 mg, at least about 16 mg, at least about 30 mg, or at least about 60 mg; <1> or <2> The PRMT5 inhibitor according to claim 1. <4> Each of the initial dose per day or each of the subsequent doses per day is independently about 0.1 to about 100 mg, about 0.5 to about 80 mg, about 0.5 to about 60 mg, 0.5 to about 30 mg, about 0.5 to about 16 mg, about 0.5 to about 8 mg, about 0.5 to about 4 mg, about 0.5 to about 2 mg, or about 0.5 to about 1 mg. <1> or <2> The PRMT5 inhibitor according to claim 1. <5> wherein each of said initial dose per day and said subsequent doses per day is independently about 0.5 mg, about 1 mg, about 1.5 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 5.5 mg, about 6 mg, about 8 mg, about 12.5 mg, about 16 mg, about 25 mg, about 30 mg, about 50 mg, about 60 mg, about 100 mg, about 200 mg, about 400 mg, about 600 mg, about 800 mg, or about 1200 mg; <1> ~ <4> The PRMT5 inhibitor according to any one of the preceding claims. <6> wherein the first dose or each of the at least one subsequent dose is administered once daily, or both the first dose and the at least one subsequent dose are administered once daily; <1> ~ <5> The PRMT5 inhibitor according to any one of the preceding claims. <7> wherein the first dose or each of the at least one subsequent dose is administered in a split dose, or both the first dose and the at least one subsequent dose are administered in a split dose; <1> ~ <5> The PRMT5 inhibitor according to any one of the preceding claims. <8> The divided doses are equal, <7> The PRMT5 inhibitor according to claim 1. <9> One or both divided doses are administered twice daily (BID); <6> ~ <8> The PRMT5 inhibitor according to any one of the preceding claims. <10> The initial administration period is about 7 days to about 14 days. <1> ~ <9> The PRMT5 inhibitor according to any one of the preceding claims. <11> The initial administration period is about 7 days. <1> ~ <10> The PRMT5 inhibitor according to any one of the preceding claims. <12> The initial administration period is about 14 days. <1> ~ <10> The PRMT5 inhibitor according to any one of the preceding claims. <13> the first subsequent administration period is spaced in time from the first administration period by at least about 7 days, and the subsequent administration periods are spaced in time from each other by at least about 7 days. <1> ~ <12> The PRMT5 inhibitor according to any one of the preceding claims. <14> the first subsequent administration period is spaced in time from the first administration period by about 7 days, and the subsequent administration periods are spaced in time from each other by about 7 days. <1> ~ <13> The PRMT5 inhibitor according to any one of the preceding claims. <15> Each subsequent administration period is about 7 days to about 14 days. <1> ~ <12> The PRMT5 inhibitor according to any one of the preceding claims. <16> Each subsequent dosing period is approximately 7 days. <1> ~ <15> The PRMT5 inhibitor according to any one of the preceding claims. <17> the first subsequent administration period is spaced in time from the first administration period by at least about 14 days, and the subsequent administration periods are spaced in time from each other by at least about 14 days. <1> ~ <12> The PRMT5 inhibitor according to any one of the preceding claims. <18> Each subsequent dosing period is approximately 14 days. <1> ~ <15> or <17> The PRMT5 inhibitor according to any one of the preceding claims. <19> the first dose or at least one of the subsequent doses is administered orally, or the first dose and at least one of the subsequent doses are administered orally; <1> ~ <18> The PRMT5 inhibitor according to any one of the preceding claims. <20> the first dose or at least one of the subsequent doses is administered parenterally, or the first dose and at least one of the subsequent doses are administered parenterally; <1> ~ <18> The PRMT5 inhibitor according to any one of the preceding claims. <21> said first dose and at least one of said subsequent doses are the same; <1> ~ <20> The PRMT5 inhibitor according to any one of the preceding claims. <22> the initial dose and at least one of the subsequent doses are different; <1> ~ <20> The PRMT5 inhibitor according to any one of the preceding claims. <23> The cancer is an advanced cancer. <1> ~ <22> The PRMT5 inhibitor according to any one of the preceding claims. <24> The cancers include acoustic neuroma, adenocarcinoma, adenoid cystic carcinoma, adrenal cancer, anal cancer, angiosarcoma, appendix cancer, benign monoclonal gammopathy, bile duct cancer, bladder cancer, breast cancer, brain tumor, bronchial cancer, carcinoid tumor, cervical cancer, chordoma, choriocarcinoma, craniopharyngioma, colorectal cancer, epithelial cancer, ependymoma, endothelial sarcoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, eye cancer, familial hypereosinophilia, gallbladder cancer, gastric cancer, gastrointestinal stromal tumor, head and neck cancer, hematopoietic cancer, heavy chain disease, hemangioblastoma, inflammatory myofibroblastic tumor, immunocytic amyloidosis, kidney cancer, liver cancer, lung cancer, leiomyosarcoma, mastocytosis, myelodysplastic syndrome, mesothelioma, myeloproliferative disorder, neuroblastoma, neurofibroma, neuroendocrine cancer, osteosarcoma, ovarian cancer, papillary adenocarcinoma, pancreatic cancer, penile cancer, pinealoma, primitive neuroectodermal tumor, prostate cancer, rectal cancer, rhabdomyosarcoma, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, sebaceous gland cancer, sweat gland cancer, synovial tumor, testicular cancer, thyroid cancer, urethral cancer, uveal melanoma, vaginal cancer, or vulvar cancer; <1> ~ <23> The PRMT5 inhibitor according to any one of the preceding claims. <25> The cancer is a solid cancer. <1> ~ <24> The PRMT5 inhibitor according to any one of the preceding claims. <26> The cancer is non-small cell lung cancer. <1> ~ <25> The PRMT5 inhibitor according to any one of the preceding claims. <27> The cancer is a hematopoietic cancer. <1> ~ <24> The PRMT5 inhibitor according to any one of the preceding claims. <28> the cancer is non-Hodgkin's lymphoma, Hodgkin's lymphoma, myeloma, CMML, MDS, or AML; <27> The PRMT5 inhibitor according to claim 1. <29> further comprising administering adjuvant therapy to said patient. <1> ~ <28> The PRMT5 inhibitor according to any one of the preceding claims. <30> The adjuvant therapy comprises administering radiation to the patient. <29> The PRMT5 inhibitor according to claim 1. <31> The adjuvant therapy comprises administering to the patient an effective amount of a chemotherapeutic agent; <29> The PRMT5 inhibitor according to claim 1. <32> The chemotherapeutic agent is a DNA methyltransferase inhibitor such as 5-azacytidine or decitabine, preferably 5-azacytidine; <31> The PRMT5 inhibitor according to claim 1. <33> Efficacy is measured by determining the time to patient disease progression or patient response rate. <1> ~ <32> The PRMT5 inhibitor according to any one of the preceding claims. <34> The compound is a pharma- ceutically acceptable addition salt of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol. <1> ~ <33> The PRMT5 inhibitor according to any one of the preceding claims. <35> The compound is a solvate of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol. <1> ~ <31> The PRMT5 inhibitor according to any one of the preceding claims. <36> The solvate is a hydrate. <35> The PRMT5 inhibitor according to claim 1. <37> The compound is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol; <1> ~ <34> The PRMT5 inhibitor according to any one of the preceding claims. <38> 1. A PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer, comprising administering to said human patient a therapeutically effective amount of said PRMT5 inhibitor, said administering comprising: (i) administering to the patient an initial dose of about 0.1 mg to about 5 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial administration period of about 14 days; (ii) administering to the patient a subsequent dose of about 0.1 mg to about 5 mg of the PRMT5 inhibitor per day for one or more subsequent administration periods; the first subsequent administration period is separated in time by at least about 7 days from said first administration period; The subsequent administration periods are separated in time from each other by at least about 7 days. <39> 1. A PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer, comprising administering to said human patient a therapeutically effective amount of said PRMT5 inhibitor, said administering comprising: (i) administering to the patient an initial dose of about 0.1 mg to about 5 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial administration period of about 14 days; (ii) administering to the patient a subsequent dose of about 0.1 mg to about 5 mg of the PRMT5 inhibitor per day for one or more subsequent administration periods; the first subsequent administration period is separated in time by at least about 14 days from said first administration period; The subsequent administration periods are separated in time from each other by at least about 14 days. <40> 1. A PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer, comprising administering to said human patient a therapeutically effective amount of said PRMT5 inhibitor, said administering comprising: (i) administering to the patient an initial dose of at least about 0.1 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial administration period of about 7 days to about 14 days; (ii) after the initial period, the PRMT5 inhibitor is not administered to the patient for an off period of about 7 days to about 14 days; (iii) administering to the patient after the off period a subsequent dose of at least about 0.1 mg of the PRMT5 inhibitor per day for a subsequent administration period of about 7 days to about 14 days; (iv) after said subsequent administration period, the compound is not administered to said patient for an off period of about 7 days to about 14 days. (v) optionally repeating steps (iii) and (iv) successively. <41> (i) administering to the patient an initial dose of at least about 0.1 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 14 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days; (iii) administering to the patient after the off period a subsequent dose of at least about 0.1 mg of the PRMT5 inhibitor per day for a subsequent dosing period of about 14 days; (iv) after said subsequent administration period, administering no more than about 7 days of the compound to said patient; and (v) optionally, repeating steps (iii) and (iv) successively. <42> (i) administering to the patient an initial dose of at least about 0.1 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 7 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days; (iii) administering to the patient after the off period a subsequent dose of at least about 0.1 mg of the PRMT5 inhibitor per day for a subsequent dosing period of about 7 days; (iv) after said subsequent administration period, administering no more than about 7 days of the compound to said patient; and (v) optionally, repeating steps (iii) and (iv) successively. <43> (i) administering to the patient an initial dose of at least about 0.1 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 7 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days; (iii) administering to the patient after the off period a subsequent dose of at least about 0.1 mg of the PRMT5 inhibitor per day for a subsequent dosing period of about 14 days; (iv) after said subsequent administration period, administering no more than about 7 days of the compound to said patient; and (v) optionally, repeating steps (iii) and (iv) successively. <44> Step (v) comprises repeating steps (iii) and (iv) consecutively at least four times; <40> ~ <43> The PRMT5 inhibitor according to any one of the preceding claims. <45> administering to the patient an initial dose of about 0.5 mg to about 5 mg of the PRMT5 inhibitor per day; and administering to the patient subsequent doses of about 0.5 mg to about 5 mg of the PRMT5 inhibitor per day. <40> ~ <44> The PRMT5 inhibitor according to any one of the preceding claims. <46> 1. A method for treating a human patient diagnosed with cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, (i) administering to the patient an initial dose of at least about 0.1 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 5 to about 21 days; (ii) administering to the patient subsequent doses of at least about 0.1 mg of the PRMT5 inhibitor per day for one or more subsequent dosing periods, each of about 5 to about 21 days; the first subsequent administration period is separated in time by at least about 5 days from said first administration period; The subsequent administration periods are spaced in time from each other by at least about 5 days. <47> the cancer is characterized by a splicing factor mutation; <46> The method described above. <48> wherein said initial dose per day or each of said subsequent doses per day is independently at least about 0.5 mg, at least about 1 mg, at least about 1.5 mg, at least about 2 mg, at least about 3 mg, at least about 4 mg, at least about 5 mg, at least about 5.5 mg, at least about 6 mg, at least about 8 mg, at least about 16 mg, at least about 30 mg, or at least about 60 mg; <46> or <47> The method described above. <49> Each of the initial dose per day or each of the subsequent doses per day is independently about 0.1 to about 100 mg, about 0.5 to about 80 mg, about 0.5 to about 60 mg, 0.5 to about 30 mg, about 0.5 to about 16 mg, about 0.5 to about 8 mg, about 0.5 to about 4 mg, about 0.5 to about 2 mg, or about 0.5 to about 1 mg. <46> ~ <48> The PRMT5 inhibitor according to any one of the preceding claims. <50> wherein each of said initial dose per day and said subsequent doses per day is independently about 0.5 mg, about 1 mg, about 1.5 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 5.5 mg, about 6 mg, about 8 mg, about 12.5 mg, about 16 mg, about 25 mg, about 30 mg, about 50 mg, about 60 mg, about 100 mg, about 200 mg, about 400 mg, about 600 mg, about 800 mg, or about 1200 mg; <46> ~ <49> 2. The method according to claim 1 , <51> wherein the first dose or each of the at least one subsequent dose is administered once daily, or both the first dose and the at least one subsequent dose are administered once daily; <46> ~ <50> 2. The method according to claim 1 , <52> wherein the first dose or each of the at least one subsequent dose is administered in a split dose, or both the first dose and the at least one subsequent dose are administered in a split dose; <46> ~ <50> 2. The method according to claim 1 , <53> The divided doses are equal, <52> The method described above. <54> One or both divided doses are administered twice daily (BID); <51> ~ <53> 2. The method according to claim 1 , <55> The initial administration period is about 7 days to about 14 days. <46> ~ <54> 2. The method according to claim 1 , <56> The initial administration period is about 7 days. <46> ~ <55> 2. The method according to claim 1 , <57> The initial administration period is about 14 days. <46> ~ <55> 2. The method according to claim 1 , <58> the first subsequent administration period is spaced in time from the first administration period by at least about 7 days, and the subsequent administration periods are spaced in time from each other by at least about 7 days. <46> ~ <57> 2. The method according to claim 1 , <59> the first subsequent administration period is spaced in time from the first administration period by about 7 days, and the subsequent administration periods are spaced in time from each other by about 7 days. <46> ~ <58> 2. The method according to claim 1 , <60> Each subsequent administration period is about 7 days to about 14 days. <46> ~ <57> 2. The method according to claim 1 , <61> Each subsequent dosing period is approximately 7 days. <46> ~ <60> 2. The method according to claim 1 , <62> the first subsequent administration period is spaced in time from the first administration period by at least about 14 days, and the subsequent administration periods are spaced in time from each other by at least about 14 days. <46> ~ <57> 2. The method according to claim 1 , <63> Each subsequent dosing period is approximately 14 days. <46> ~ <60> or <62> 2. The method according to claim 1 , <64> the first dose or at least one of the subsequent doses is administered orally, or the first dose and at least one of the subsequent doses are administered orally; <46> ~ <63> 2. The method according to claim 1 , <65> the first dose or at least one of the subsequent doses is administered parenterally, or the first dose and at least one of the subsequent doses are administered parenterally; <46> ~ <63> 2. The method according to claim 1 , <66> said first dose and at least one of said subsequent doses are the same; <46> ~ <65> 2. The method according to claim 1 , <67> the initial dose and at least one of the subsequent doses are different; <46> ~ <65> 2. The method according to claim 1 , <68> The cancer is an advanced cancer. <46> ~ <67> 2. The method according to claim 1 , <69> The cancers include acoustic neuroma, adenocarcinoma, adenoid cystic carcinoma, adrenal cancer, anal cancer, angiosarcoma, appendix cancer, benign monoclonal gammopathy, bile duct cancer, bladder cancer, breast cancer, brain tumor, bronchial cancer, carcinoid tumor, cervical cancer, chordoma, choriocarcinoma, craniopharyngioma, colorectal cancer, epithelial cancer, ependymoma, endothelial sarcoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, eye cancer, familial hypereosinophilia, gallbladder cancer, gastric cancer, gastrointestinal stromal tumor, head and neck cancer, hematopoietic cancer, heavy chain disease, hemangioblastoma, inflammatory myofibroblastic tumor, immunocytic amyloidosis, kidney cancer, liver cancer, lung cancer, leiomyosarcoma, mastocytosis, myelodysplastic syndrome, mesothelioma, myeloproliferative disorder, neuroblastoma, neurofibroma, neuroendocrine cancer, osteosarcoma, ovarian cancer, papillary adenocarcinoma, pancreatic cancer, penile cancer, pinealoma, primitive neuroectodermal tumor, prostate cancer, rectal cancer, rhabdomyosarcoma, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, sebaceous gland cancer, sweat gland cancer, synovial tumor, testicular cancer, thyroid cancer, urethral cancer, uveal melanoma, vaginal cancer, or vulvar cancer; <46> ~ <68> 2. The method according to claim 1 , <70> The cancer is a solid cancer. <46> ~ <69> 2. The method according to claim 1 , <71> The cancer is non-small cell lung cancer. <46> ~ <70> 2. The method according to claim 1 , <72> The cancer is a hematopoietic cancer. <46> ~ <69> 2. The method according to claim 1 , <73> the cancer is non-Hodgkin's lymphoma, Hodgkin's lymphoma, myeloma, CMML, MDS, or AML; <72> The method described above. <74> further comprising administering adjuvant therapy to said patient. <46> ~ <73> 2. The method according to claim 1 , <75> The adjuvant therapy comprises administering radiation to the patient. <74> The method described above. <76> The adjuvant therapy comprises administering to the patient an effective amount of a chemotherapeutic agent; <74> The method described above. <77> The chemotherapeutic agent is a DNA methyltransferase inhibitor such as 5-azacytidine or decitabine, preferably 5-azacytidine; <76> The method described above. <78> Efficacy is measured by determining the time to patient disease progression or patient response rate. <46> ~ <77> 2. The method according to claim 1 , <79> The compound is a pharma- ceutically acceptable addition salt of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol. <46> ~ <78> 2. The method according to claim 1 , <80> The compound is a solvate of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol. <46> ~ <76> 2. The method according to claim 1 , <81> The solvate is a hydrate. <80> The method described above. <82> The compound is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol; <46> ~ <79> 2. The method according to claim 1 , <83> 1. A method for treating a human patient diagnosed with cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, (i) administering to the patient an initial dose of about 0.1 mg to about 5 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial administration period of about 14 days; (ii) administering to the patient a subsequent dose of about 0.1 mg to about 5 mg of the PRMT5 inhibitor per day for one or more subsequent administration periods; the first subsequent administration period is separated in time by at least about 7 days from said first administration period; The subsequent administration periods are spaced in time from each other by at least about 7 days. <84> 1. A method for treating a human patient diagnosed with cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, (i) administering to the patient an initial dose of about 0.1 mg to about 5 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial administration period of about 14 days; (ii) administering to the patient a subsequent dose of about 0.1 mg to about 5 mg of the PRMT5 inhibitor per day for one or more subsequent administration periods; the first subsequent administration period is separated in time by at least about 14 days from said first administration period; The subsequent administration periods are separated in time from each other by at least about 14 days. <85> 1. A method for treating a human patient diagnosed with cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, (i) administering to the patient an initial dose of at least about 0.1 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial administration period of about 7 days to about 14 days; (ii) after the initial period, the PRMT5 inhibitor is not administered to the patient for an off period of about 7 days to about 14 days; (iii) administering to the patient after the off period a subsequent dose of at least about 0.1 mg of the PRMT5 inhibitor per day for a subsequent administration period of about 7 days to about 14 days; (iv) after said subsequent administration period, the compound is not administered to said patient for an off period of about 7 days to about 14 days. (v) optionally repeating steps (iii) and (iv) successively. <86> (i) administering to the patient an initial dose of at least about 0.1 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 14 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days; (iii) administering to the patient after the off period a subsequent dose of at least about 0.1 mg of the PRMT5 inhibitor per day for a subsequent dosing period of about 14 days; (iv) after said subsequent administration period, administering no more than about 7 days of the compound to said patient; and (v) optionally repeating steps (iii) and (iv) successively; <85> The method according to <87> (i) administering to the patient an initial dose of at least about 0.1 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 7 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days; (iii) administering to the patient after the off period a subsequent dose of at least about 0.1 mg of the PRMT5 inhibitor per day for a subsequent dosing period of about 7 days; (iv) after said subsequent administration period, administering no more than about 7 days of the compound to said patient; and (v) optionally repeating steps (iii) and (iv) successively; <85> The method according to <88> (i) administering to the patient an initial dose of at least about 0.1 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 7 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days; (iii) administering to the patient after the off period a subsequent dose of at least about 0.1 mg of the PRMT5 inhibitor per day for a subsequent dosing period of about 14 days; (iv) after said subsequent administration period, administering no more than about 7 days of the compound to said patient; and (v) optionally repeating steps (iii) and (iv) successively; <85> The method according to <89> Step (v) comprises repeating steps (iii) and (iv) consecutively at least four times; <85> ~ <88> 2. The method according to claim 1 , <90> administering to the patient an initial dose of about 0.5 mg to about 5 mg of the PRMT5 inhibitor per day; and administering to the patient subsequent doses of about 0.5 mg to about 5 mg of the PRMT5 inhibitor per day. <85> ~ <89> 2. The method according to claim 1 , <91> Use of a PRMT5 (protein arginine methyltransferase 5) inhibitor in the manufacture of a medicament for treating a human patient diagnosed with cancer, comprising administering a therapeutically effective amount of said PRMT5 inhibitor, i.e. (i) administering to the patient an initial dose of at least about 0.1 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 5 to about 21 days; (ii) administering to the patient subsequent doses of at least about 0.1 mg of the PRMT5 inhibitor per day for one or more subsequent dosing periods, each of about 5 to about 21 days; the first subsequent administration period is separated in time by at least about 5 days from said first administration period; The subsequent administration periods are spaced in time from each other by at least about 5 days. <92> 1. Use of a PRMT5 (protein arginine methyltransferase 5) inhibitor in the manufacture of a medicament for treating a human patient diagnosed with cancer, comprising: (i) administering to the patient an initial dose of about 0.1 mg to about 5 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial administration period of about 14 days; and (ii) administering to the patient a therapeutically effective amount of the PRMT5 inhibitor by administering to the patient a subsequent dose of about 0.1 mg to about 5 mg of the PRMT5 inhibitor per day for one or more subsequent administration periods; the first subsequent administration period is separated in time by at least about 7 days from said first administration period; The subsequent administration periods are spaced in time from each other by at least about 7 days. <93> 1. Use of a PRMT5 (protein arginine methyltransferase 5) inhibitor in the manufacture of a medicament for treating a human patient diagnosed with cancer, comprising: (i) administering to the patient an initial dose of about 0.1 mg to about 5 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial administration period of about 14 days; and (ii) administering to the patient a therapeutically effective amount of the PRMT5 inhibitor by administering to the patient a subsequent dose of about 0.1 mg to about 5 mg of the PRMT5 inhibitor per day for one or more subsequent administration periods; the first subsequent administration period is separated in time by at least about 14 days from said first administration period; The subsequent administration periods are separated in time from each other by at least about 14 days. <94> 1. Use of a PRMT5 (protein arginine methyltransferase 5) inhibitor in the manufacture of a medicament for treating a human patient diagnosed with cancer, comprising: (i) administering to the patient an initial dose of at least about 0.1 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 7 days to about 14 days; (ii) after the initial period, the PRMT5 inhibitor is not administered to the patient for an off period of about 7 days to about 14 days; (iii) administering to the patient after the off period a subsequent dose of at least about 0.1 mg of the PRMT5 inhibitor per day for a subsequent administration period of about 7 days to about 14 days; (iv) after said subsequent administration period, the compound is not administered to said patient for an off period of about 7 days to about 14 days; and (v) Optionally, the use comprises administering a therapeutically effective amount of said PRMT5 inhibitor by continuously repeating steps (iii) and (iv).
Claims
1. 1. A pharmaceutical composition comprising a PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer, comprising: said treatment comprising administering to said human patient a therapeutically effective amount of said PRMT5 inhibitor; The administration comprises: (i) administering to the patient an initial dose of about 0.5 to about 2 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 5 to about 21 days; (ii) administering to the patient subsequent doses of about 0.5 to about 2 mg of the PRMT5 inhibitor per day for one or more subsequent dosing periods, each of about 5 to about 21 days; the first subsequent administration period is separated in time by at least about 5 days from said first administration period; When there is more than one subsequent administration period, said subsequent administration periods are separated in time by at least about 5 days from each other.
2. The method of claim 1 , wherein the cancer is characterized by a splicing factor mutation.
3. said initial dose per day or each of said subsequent doses per day is independently at least about 0.5 mg, at least about 1 mg, at least about 1.5 mg, or at least about 2 mg; said initial dose per day or each of said subsequent doses per day is independently from about 0.5 to about 1 mg; and / or each of said initial dose per day and said subsequent doses per day is independently about 0.5 mg, about 1 mg, about 1.5 mg, or about 2 mg; The pharmaceutical composition according to claim 1 or 2.
4. (a) the first dose or each of the at least one subsequent dose is administered once daily, or both the first dose and the at least one subsequent dose are administered once daily; (b) the initial dose or each of the at least one subsequent dose is administered in a split dose, or both the initial dose and the at least one subsequent dose are administered in a split dose; and / or One or both divided doses are administered twice daily (BID); The pharmaceutical composition according to any one of claims 1 to 3.
5. the initial administration period is from about 7 days to about 14 days; and / or The initial administration period is (a) For about seven days, (b) Approximately 14 days; The pharmaceutical composition according to any one of claims 1 to 4.
6. (a) the first subsequent administration period is spaced in time from the first administration period by at least about 7 days, and the subsequent administration periods are spaced in time from each other by at least about 7 days; and / or said first subsequent administration period is spaced in time from said first administration period by about 7 days, and if there is more than one subsequent administration period, said subsequent administration periods are spaced in time from each other by about 7 days; (b) each subsequent administration period is from about 7 days to about 14 days; The pharmaceutical composition according to any one of claims 1 to 5.
7. The pharmaceutical composition of any one of claims 1 to 6, wherein each subsequent administration period is for about 7 days.
8. 6. The pharmaceutical composition of any one of claims 1 to 5, wherein the first subsequent administration period is spaced in time from the first administration period by at least about 14 days, and when there is more than one subsequent administration period, the subsequent administration periods are spaced in time from each other by at least about 14 days.
9. The pharmaceutical composition of any one of claims 1 to 6 or 8, wherein each subsequent administration period is for about 14 days.
10. (a) the first dose or at least one of the subsequent doses is administered orally, or the first dose and at least one of the subsequent doses are administered orally; (b) the first dose or at least one of the subsequent doses is administered parenterally, or the first dose and at least one of the subsequent doses are administered parenterally; The pharmaceutical composition according to any one of claims 1 to 9.
11. (a) the first dose and at least one of the subsequent doses are the same; (b) the first dose and at least one of the subsequent doses are different; The pharmaceutical composition according to any one of claims 1 to 10.
12. (a) the cancer is advanced cancer; and / or (b) the cancer is selected from the group consisting of acoustic neuroma, adenocarcinoma, adenoid cystic carcinoma, adrenal carcinoma, anal carcinoma, angiosarcoma, appendix carcinoma, benign monoclonal gammopathy, bile duct carcinoma, bladder carcinoma, breast cancer, brain tumor, bronchial carcinoma, carcinoid tumor, cervical carcinoma, chordoma, choriocarcinoma, craniopharyngioma, colorectal carcinoma, epithelial carcinoma, ependymoma, endothelial sarcoma, endometrial carcinoma, esophageal carcinoma, Ewing's sarcoma, eye cancer, familial hypereosinophilia, gallbladder carcinoma, gastric cancer, gastrointestinal stromal tumor, head and neck cancer, hematopoietic cancer, heavy chain disease, hemangioblastoma, inflammatory myofibroblastic tumor, immunocytic amyloidosis, kidney cancer, liver cancer, lung cancer, leiomyosarcoma, mastocytosis, myelodysplastic syndrome, mesothelioma, myeloproliferative disorder, neuroblastoma, neurofibroma, neuroendocrine cancer, osteosarcoma, ovarian cancer, papillary adenocarcinoma, pancreatic cancer, penile cancer, pinealoma, primitive neuroectodermal tumor, prostate cancer, rectal cancer, rhabdomyosarcoma, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, sebaceous gland cancer, sweat gland cancer, synovial tumor, testicular cancer, thyroid cancer, urethral cancer, uveal melanoma, vaginal cancer, or vulvar cancer; The pharmaceutical composition according to any one of claims 1 to 11.
13. (a) the cancer is a solid tumor; and / or is the cancer non-small cell lung cancer; the cancer is a hematopoietic cancer; A pharmaceutical composition according to any one of claims 1 to 12.
14. The pharmaceutical composition of any one of claims 1 to 13, further comprising administering an adjuvant therapy to said patient.
15. The pharmaceutical composition according to any one of claims 1 to 14, wherein efficacy is measured by determining the patient's time to disease progression or patient response rate.
16. The compound is (a) a pharma- ceutically acceptable addition salt of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol; (b) a solvate of (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol; (c) (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol. A pharmaceutical composition according to any one of claims 1 to 15.
17. 1. A pharmaceutical composition comprising a PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer, comprising: said treatment comprising administering to said human patient a therapeutically effective amount of said PRMT5 inhibitor; The administration comprises: (i) administering to the patient an initial dose of about 0.5 mg to about 2 mg per day of the PRMT5 inhibitor which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 14 days; (ii) administering to the patient a subsequent dose of about 0.5 mg to about 2 mg of the PRMT5 inhibitor per day for one or more subsequent dosing periods; (a) a first subsequent administration period is separated in time by at least about 7 days from said first administration period; If there is more than one subsequent administration period, the subsequent administration periods are separated in time from each other by at least about 7 days; (b) a first subsequent administration period is separated in time by at least about 14 days from said first administration period; When there is more than one subsequent administration period, said subsequent administration periods are separated in time by at least about 14 days from each other.
18. 1. A pharmaceutical composition comprising a PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer, comprising: said treatment comprising administering to said human patient a therapeutically effective amount of said PRMT5 inhibitor; The administration comprises: (i) administering to the patient an initial dose of about 0.5 to about 2 mg per day of the PRMT5 inhibitor which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 7 days to about 14 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days to about 14 days; (iii) after the off period, administering to the patient a subsequent dose of about 0.5 to about 2 mg of the PRMT5 inhibitor per day for a subsequent dosing period of about 7 days to about 14 days; (iv) after said subsequent administration period, administering to said patient no compound for an off period of about 7 days to about 14 days; and 13. A pharmaceutical composition comprising:
19. (a) (i) administering to the patient an initial dose of about 0.5 to about 2 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 14 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days; (iii) after the off period, administering to the patient a subsequent dose of about 0.5 to about 2 mg of the PRMT5 inhibitor per day for a subsequent dosing period of about 14 days; (iv) after said subsequent administration period, administering no compound to said patient for an off period of about 7 days; (b) (i) administering to the patient an initial dose of about 0.5 to about 2 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 7 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days; (iii) after the off period, administering to the patient a subsequent dose of about 0.5 to about 2 mg of the PRMT5 inhibitor per day for a subsequent dosing period of about 7 days; (iv) after said subsequent administration period, administering no compound to said patient for an off period of about 7 days; (c) (i) administering to the patient an initial dose of about 0.5 to about 2 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 7 days; (ii) after the initial period, not administering the PRMT5 inhibitor to the patient for an off period of about 7 days; (iii) after the off period, administering to the patient a subsequent dose of about 0.5 to about 2 mg of the PRMT5 inhibitor per day for a subsequent dosing period of about 14 days; (iv) after said subsequent administration period, administering no more than about 7 days of the compound to said patient; and 20. The pharmaceutical composition of claim 18, comprising:
20. 1. A pharmaceutical composition comprising a PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer, comprising: said treatment comprising administering to said human patient a therapeutically effective amount of said PRMT5 inhibitor; said administering comprising intermittently administering about 1.5 mg of said PRMT5 inhibitor which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof; The pharmaceutical composition, wherein the PRMT5 inhibitor is administered once daily for about 14 consecutive days in a 21-day cycle, followed by about 7 days off.
21. 1. A pharmaceutical composition comprising a PRMT5 (protein arginine methyltransferase 5) inhibitor for use in treating a human patient diagnosed with cancer, comprising: said treatment comprising administering to said human patient a therapeutically effective amount of said PRMT5 inhibitor; The pharmaceutical composition, wherein the administration comprises administering about 1 mg of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, once daily.
22. said treatment comprising administering to said human patient a therapeutically effective amount of said PRMT5 inhibitor; The administration comprises: (i) administering an initial dose of about 1.5 mg once daily of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 14 days; (ii) administering a subsequent dose of about 1.5 mg of said PRMT5 inhibitor once daily for one or more subsequent dosing periods of about 14 days; the first subsequent administration period is separated in time by at least about 7 days from said first administration period; When there is more than one subsequent administration period, the subsequent administration periods are separated in time from each other by at least about 7 days.
21. The pharmaceutical composition of claim 20.
23. said treatment comprising administering to said human patient a therapeutically effective amount of said PRMT5 inhibitor; The administration comprises: (i) administering an initial dose of about 1.5 mg once daily of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 14 days; (ii) after said first administration, said PRMT5 inhibitor is not administered for an off period of about 7 days; (iii) following the off period, administering a subsequent dose of about 1.5 mg of the PRMT5 inhibitor once daily for a subsequent dosing period of about 14 days; (iv) after the subsequent administration period, the PRMT5 inhibitor is not administered for an off period of about 7 days. Including, 21. The pharmaceutical composition of claim 20.
24. The PRMT5 inhibitor, (a) once daily for an initial administration period of about 21 days; or (b) administered once daily for an initial administration period of about 21 days and one or more subsequent administration periods each of about 21 days; 22. The pharmaceutical composition of claim 21.
25. The pharmaceutical composition of any one of claims 20 to 24, wherein the cancer is characterized by a splicing factor mutation.
26. The pharmaceutical composition according to any one of claims 20 to 25, wherein the cancer is an advanced cancer.
27. The pharmaceutical composition of any one of claims 20 to 26, wherein the PRMT5 inhibitor is administered orally.
28. 1. Use of a PRMT5 (protein arginine methyltransferase 5) inhibitor in the manufacture of a medicament for treating a human patient diagnosed with cancer, comprising: The medicament comprises the PRMT5 inhibitor, The treatment comprises administering a therapeutically effective amount of the PRMT5 inhibitor, the administration being in any of the following ways: (a) to (d): (a) (i) administering to the patient an initial dose of about 0.5 to about 2 mg per day of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 5 to about 21 days; (ii) administering to said patient subsequent doses of about 0.5 to about 2 mg of said PRMT5 inhibitor per day for one or more subsequent dosing periods, each of about 5 to about 21 days, the first subsequent administration period is separated in time by at least about 5 days from said first administration period; when there is more than one subsequent administration period, the subsequent administration periods are separated in time by at least about 5 days from each other; (b) (i) administering to the patient an initial dose of about 0.5 mg to about 2 mg per day of the PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 14 days; and (ii) administering to said patient a subsequent dose of about 0.5 mg to about 2 mg of said PRMT5 inhibitor per day for one or more subsequent dosing periods, the first subsequent administration period is separated in time by at least about 7 days from said first administration period; when there is more than one subsequent administration period, said subsequent administration periods are separated in time from each other by at least about 7 days; (c) (i) administering to the patient an initial dose of about 0.5 mg to about 2 mg per day of the PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 14 days; and (ii) administering to said patient a subsequent dose of about 0.5 mg to about 2 mg of said PRMT5 inhibitor per day for one or more subsequent dosing periods, the first subsequent administration period is separated in time by at least about 14 days from said first administration period; or, when there is more than one subsequent administration period, the subsequent administration periods are separated in time from each other by at least about 14 days; (d) (i) administering to the patient an initial dose of about 0.5 to about 2 mg per day of the PRMT5 inhibitor which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 7 days to about 14 days; (ii) after said initial period, said patient is not administered said PRMT5 inhibitor for an off period of about 7 days to about 14 days; (iii) after said off period, administering to said patient a subsequent dose of about 0.5 to about 2 mg of said PRMT5 inhibitor per day for a subsequent dosing period of about 7 days to about 14 days; and (iv) after said subsequent administration period, said compound is not administered to said patient for an off period of about 7 days to about 14 days; Used by.
29. 1. Use of a PRMT5 (protein arginine methyltransferase 5) inhibitor in the manufacture of a medicament for treating a human patient diagnosed with cancer, comprising: The medicament comprises the PRMT5 inhibitor, said treatment comprising administering to said human patient a therapeutically effective amount of said PRMT5 inhibitor; said administering comprising intermittently administering about 1.5 mg of said PRMT5 inhibitor which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof; The PRMT5 inhibitor is administered continuously for about 14 days, followed by about 7 days off, in a 21-day cycle. use.
30. 1. Use of a PRMT5 (protein arginine methyltransferase 5) inhibitor in the manufacture of a medicament for treating a human patient diagnosed with cancer, comprising: The medicament comprises the PRMT5 inhibitor, said treatment comprising administering to said human patient a therapeutically effective amount of said PRMT5 inhibitor; The administration comprises administering about 1 mg of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, once daily.
31. said treatment comprising administering to said human patient a therapeutically effective amount of said PRMT5 inhibitor; The administration comprises: (i) administering an initial dose of about 1.5 mg once daily of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 14 days; (ii) administering a subsequent dose of about 1.5 mg of said PRMT5 inhibitor once daily for one or more subsequent dosing periods of about 14 days; the first subsequent administration period is separated in time by at least about 7 days from said first administration period; When there is more than one subsequent administration period, the subsequent administration periods are separated in time from each other by at least about 7 days.
30. The use according to claim 29.
32. said treatment comprising administering to said human patient a therapeutically effective amount of said PRMT5 inhibitor; The administration comprises: (i) administering an initial dose of about 1.5 mg once daily of the PRMT5 inhibitor, which is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharma- ceutically acceptable addition salt or solvate thereof, for an initial dosing period of about 14 days; (ii) after said first administration, said PRMT5 inhibitor is not administered for an off period of about 7 days; (iii) following the off period, administering a subsequent dose of about 1.5 mg of the PRMT5 inhibitor once daily for a subsequent dosing period of about 14 days; (iv) after the subsequent administration period, the PRMT5 inhibitor is not administered for an off period of about 7 days; 30. The use according to claim 29, comprising:
33. The PRMT5 inhibitor, (a) once daily for an initial administration period of about 21 days; or (b) administered once daily for an initial administration period of about 21 days and one or more subsequent administration periods each of about 21 days; 31. The use according to claim 30.
34. The use according to any one of claims 29 to 33, wherein the cancer is characterized by a splicing factor mutation.
35. The use according to any one of claims 29 to 34, wherein the cancer is an advanced cancer.
36. The use according to any one of claims 29 to 35, wherein the PRMT5 inhibitor is administered orally.
Citation Information
Patent Citations
Novel 6-6 bicyclic aromatic ring-substituted nucleoside analogues for use as prmt5 inhibitors
JP2018528946A
